Glucocorticoids, vitamin D and bone : a pathophysiologic and therapeutic study of glucocorticoid-induced bone disease by Braun, J.J. (Jacob Johannes)
GLUCOCORTICO!DS, VITAMIN D AND BONE. 
A PATHOPHYSIOLOGIC AND THERAPEUTIC STUDY OF 
GLUCOCORTICOID-INDUCED BONE DISEASE. 

GLUCOCORTICOIDS, 
VITAMIN D AND BONE. 
A PATHOPHYSIOLOGIC AND THERAPEUTIC STUDY OF 
GLUCOCORTICOID-INDUCED BONE DISEASE. 
Glucocorticoiden, vitamine D en botweefsel. 
Pathophysiologische en therapeutische aspecten van 
glucocorticoid-osteoporose. 
PROEFSCHRIFT 
TER VERKR!JGING VAN DE GRAAD VAN DOCTOR IN DE 
GENEESKUNDE 
AAN DE ERASMUS UN!VERSITEIT ROTTERDAM 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. M. W. VAN HOF 
EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. 
DE OPENBARE VERDEDIG!NG ZAL PLAATSVINDEN OP 
WOENSDAG 23 MEl 1984 TE 15.45 UUR. 
DOOR 
Jacob Johannes Braun 
geboren te Dordrecht 
Promotor: Prof. Dr. J. C. Birkenhager 
Promotiecommissie: Prof. Dr. R. 0. van der Heul 
Prof. Dr. W. C. HUismann 
Prof. J. H. P. Wilson 
The support from Leo, Pharmaceutical Products, Holland for the publication of this manuscript is 
gratefully acknowledged. 
Aan Birgit 
Annemarie, Saskia en Hanneke 
Aan mijn moeder 
ter herinnering aan mijn vader 

CONTENTS 
List of abbreviations 
CHAPTER! 
INTRODUCTION AND OBJECTIVES 
CHAPTER!! 
PHYSIOLOGY AND PATHOLOGY OF SKELETAL MASS 
2.1 Physiological changes 
2.2 Non-invasive measurements of bone (mineral) mass 
2.3 Histomorphometry, the concept of the basic multicellular unit 
2.4 Osteopenia and osteoporosis 
CHAPTER Ill 
REGULATORS OF CALCIUM HOMEOSTASIS AND SKELETAL 
MASS 
3.1 Parathyroid hormone 
3.2 Calcitonin 
3.3 Vitamin D 
3.3.1 Production 
3.3.2 Regulation 
3.3.3 Functions 
3.3.4 Vitamin D and osteoporosis 
3.4 Other hormones. 
CHAPTER IV 
INTERACTION BETWEEN GLUCOCORTICO!DS, CALCIUM 
HOMEOSTASIS AND BONE 
4.1 Parathyroid hormone 
4.1.1 Interaction with physiologic levels of glucocorticoids 
4.1.2 Interaction with supraphysiologic levels of glucocorticoids 
(short-term) 
4.1.3 Interaction with supra physiologic levels of glucorticoids 
(long-term) 
4.2 Calcitonin 
4.2.1 Interaction with physiologic levels of glucocorticoids 
4.2.2 Interaction with supraphysiologic levels of glucocorticoids 
4.3 Vitamin D metabolism 
4.3.1 Interaction with supra physiologic levels of glucocorticoids 
(short-term) 
4.3.2 Interaction with supra physiologic levels of glucocorticoids 
(long-term) 
page 
3 
3 
4 
4 
7 
8 
8 
12 
13 
14 
15 
4.4 Influence of glucocorticoid excess on other hormones 
4.4.1 Thyroid hormones 
4.4.2 Gonadal hormones 
4.4.3 Growth hormone 
4.4.41nsulin 
16 
4.5 Gastrointestinal Ca absorption and glucocorticoid excess 17 
4.5.1 Measurements in vivo 
4.5.2 Measurements in vitro 
4.5.3 Mechanism of action 
4.6 Renal handling of calcium and phosphorus during glucocorticoid 
excess 18 
4.71nfluence of glucocorticoid excess on skeletal tissue 19 
4.7.1 Histology and histomorphometry 
4. 7.2 Bone cultures in vitro 
4.7 .3 Interactions between glucocorticoids and vitamin D and 
parathyroid hormone at the (sub)cellular level 
4.8 The pathogenesis of glucocorticoid induced bone disease 21 
CHAPTERV 
SHORT -TERM EFFECT OF PREDNISONE OR HYDROCORTISONE 
ON SERUM 1,25-DIHYDROXYVITAMIN DIN NORMAL 
INDIVIDUALS AND PATIENTS WITH HYPER- AND 
HYPOPARATHYROIDISM 
Summary 23 
Introduction 23 
Patients and Methods 24 
Results 26 
Discussion 31 
CHAPTER VI 
CALCIUM AND GLUCOSE UPTAKE IN RAT SMALL INTESTINAL 
BRUSH BORDER MEMBRANE VESICLES: MODULATION BY 
EXOGENOUS HYPERCORTISOLISM AND 1,25-DIHYDROXY-
VITAMIND3 
Summary 35 
Introduction 36 
Materials and Methods 36 
Results 39 
Discussion 44 
CHAPTERV!l 
INFLUENCE OF TRIAMCINOLONE ON CALCIUM AND WATER 
ABSORPTION IN RAT SMALL INTESTINAL LOOPS IN SITU 
Introduction 
Materials and Methods 
47 
47 
Results 
Discussion 
Conclusions 
CHAPTER VIII 
INFLUENCE OF la-(OH)D3 ADMINISTRATION ON BONE AND 
BONE MINERAL METABOLISM INPATIENTS ON CHRONIC 
GLUCOCORTICOID TREATMENT; A DOUBLE-BLIND 
CONTROLLED STUDY 
49 
51 
53 
Summary 55 
Introduction 56 
Patients and Methods 56 
Results 58 
Initial investigations 
Double-blind placebo-controlled trial with la-(OH)D3 
Discussion 63 
CHAPTER IX 
COMPARISON OF INTESTINAL RADIOCALCIUM ABSORPTION 
AND INTESTINAL CALCIUM BALANCE IN PATIENTS TREATED 
WITH GLUCOCORTICOIDS WITH AND WITHOUT Ia-(OH)D3 
Introduction 67 
Methods 67 
Results 68 
Discussion 69 
Conclusions 70 
CHAPTER X 
GENERAL DISCUSSION 71 
SUMMARY 75 
SAMENVATTING 83 
REFERENCES 87 
VERANTWOORDING 101 
CURRICULUM VITAE 103 
LIST OF ABBREVIATIONS 
BBMV: brush border membrane vesicles 
BMU: basic multicellular unit 
cAMP: cyclic adenosine Y, 51-monophosphate 
CT: calcitonine 
GC: glucocorticoid(s) 
HP: hypoparathyroidism 
(i)PTH: (immunoreactive) parathyroid hormone 
PHP: primary hyperparathyroidism 
T A: triamcinolone-acetonide 
25-(0H)D: 25-hydroxyvitamin D 
1,25-(0H),D: 1,25-dihydroxyvitamin D 
la-(OH)D3: 1-alpha-hydroxyvitamin D3 
24,25-(0H)2D: 24,25-dihydroxyvitamin D 
Definitions in relation to intestinal calcium absorption studies: 
Ca-efflux: unidirectional movement of calcium from the intestinal lumen to tissue. 
Ca-influx: unidirectional movement of calcium from tissue into the intestinal 
lumen. 
CHAPTER! 
Introduction and objectives 
Mooser's report ( 1921) of a patient with osteoporosis and obesity is one of the first 
descriptions of endogenous hypercortisolism. Later Cushing (1932) described the 
syndrome as a clinical entity and Albright et al. (1941) reported 9 patients who at 
autopsy all appeared to have sustained a severe degree of cortical and trabecular 
bone loss. In 1949 glucocorticoids (GC) became available as therapeutic agents. in 
addition to their favourable antiinflammatory action deleterious side effects (e.g. 
on bone mass) have become apparent (Kjellstrand, 1975). 
A diminished bone mass, measured as trabecular bone volume of iliac crest 
biopsies (Birkenhager et al., 1967) or by total body Ca with neutron activation 
analysis (Aloia et al., 1974), is a typical hallmark in patients with endogenous 
hypercortisolism. The impact of exogenous GC excess on bone mass is more 
difficult to evaluate. In the quantification of the amount of bone in such patients 
by several techniques one has to take into account not only the physiological age 
related bone loss (see Chapter II), but also the underlying disease for which GC are 
prescribed. This is illustrated by Stresemann & Krokowski ( 1967) who found signs 
of a decreased bone mineral content on X-rays of the vertebral column (using a 
quantitative measurement technique) in 32% of patients treated with varying 
doses of GC for chronic obstructive lung disease, but similar signs were observed 
in an equal percentage of patients who never had used steroids. However, Adinof 
& Hollister (1983) described a significant loss of trabecular bone mass at the 
metaphysis of the radius with single photonabsorptiometry only in asthmatic 
subjects on long-term daily steroids. Measurement of total body Ca with neutron 
activation analysis showed lower values in patients with rheumatoid arthritis 
treated with non steroidal antiinflammatory drugs than controls, but even lower 
values in rheumatic patients treated with steroids (Reid et a!., 1982). Similar 
findings were reported by Hahn et al. (J 973) with photonabsortiometry of the 
metaphyseal mass of the forearm. The decreased mineral content was correlated 
with the duration of GC therapy. 
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Trabecular bone is specially vulnerable for the deleterious effects of GC. Using 
single photonabsorptiometry of the proximal part of the radius alone (Gluck et 
al., 1981) or combined with dual photoabsorptiometry of the lumbar spine 
(Seeman et al., I982), patients with exogenous or endogenous hypercortisolism 
have been found to have low density values at these sites. In a retrospective 
evaluation of iliac crest biopsies Bressot et al. (I979) found trabecular bone 
volumes of less than I I% of total bone volume in 42 of 62 patients chronically 
treated with GC. 
Extensive studies of physiologic and pathologic loss of bone mass have failed to 
provide a unifying concept for the pathogenesis of the common forms of osteopo-
rosis. The pathophysiology of the osteoporosis which developes during GC excess 
is also not clear. We therefore decided to study the relationships between GC, 
factors thought to be involved in bone mineral homeostasis and the target organs 
of such factors. We investigated the effects of GC on: 
1. vitamin D activation and metabolism, 
2. the secretion and activity of parathyroid hormone (PTH), 
3. the mechanism by which GC decrease intestinal Ca absorption and 
4. the possible interrelation between these processes. 
Active vitamin D metabolites have recently become available for clinical admini-
stration. The findings of this study therefore could have practical implications for 
the prophylaxis of GC induced osteoporosis. 
We looked at the influence of short-term GC excess on vitamin D metabolism in 
man at several levels of parathyroid activity (Chapter V). The mutually antagonis-
tic effects of GC and vitamin D on intestinal Ca absorption has been studied on a 
subcellular level in rat intestinal brush border membrane vesicles (BBMV) and in 
the in situ ligated gut loop (Chapters VI and VII). Finally, in line with a concept of 
the pathophysiology of GC induced bone disease as outlined in Chapter IV, a 
double-blind placebo-controlled trial with Ia-(OH)D3 is described, which we 
performed in patients on long-term corticosteroid treatment. The patients were 
matched for age, sex, dose of GC and underlying disease (Chapter VIII). In 
Chapters II and III the physiology and pathology of the skeletal mass in relation to 
Ca homeostasis is discussed. Special emphasis is given to the regulation of vitamin 
D activation and the effects of vitamin Don gastrointestinal Ca absorption. 
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CHAPTER II 
Physiology and pathology of skeletal mass. 
2.1 Physiological changes 
Skeletal weight increases during human life in both sexes with equal velocity up till 
the pubertal growth spurt. During this period of accelerated growth boys gain 
more bone, in concert with lean body mass, than girls (Garn, 1981). Beyond the 
age of 35 years the weight of the skeleton decreases gradually; this physiologic 
process starts somewhat earlier and progresses faster in females than in males. In 
1960 Trotter et al., studying postmortal skeletons, described in a cross-sectional 
study an age related loss of bone density. Besides this aging process the influence of 
racial factors, socio-economic status, food composition and physical activity on 
the weight and density of the skeleton is probably important, but not always easy 
to assess. Some aspects will be discussed later in this Chapter in relation to the 
pathophysiology of primary osteoporosis. 
2.2 Non-invasive measurements of bone (mineral) mass. 
Age related changes in total body Ca, 99% of which is located in the skeleton, can 
be measured in vivo by means of neutron activation analysis (Cohn et al., 1976), but 
this technique is not widely available. As a substitute for the measurement of 
skeletal mass (that is the total amount of bone mineral) radiographic morphometry, 
measuring for example cortical area, has been used in large cross-sectional popula-
tion surveys (Garnet al., 1967). With this and other techniques such as single 
photonabsorptiometry of the radius the sex difference and the bone loss with age 
have been documented (Smith et al., 1975) for the amount of cortical bone in those 
locations. In normal subjects the amount of cortical bone in general correlates 
quite well with the total skeletal (mineral) mass (Manzke et al., 1975; Horsman et 
al., 1983). However, in osteoporotics changes in these parameters do not need to 
correlate (Aloia et al., !975). Dual photonabsorptiometry and computer assisted 
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tomography can provide data with regard to the amount of mineral in the 
vertebrae (usually the lumbar ones), which largely consist of trabecular bone, Also 
with these techniques age related bone loss is apparent on cross-sectional surveys 
(Riggs et aL, 1981; Cann & Genant, 1982) and in a longitudinal study Kmlner & 
Nielsen (1982) found evidence for an accelerated loss of lumbar bone mineral 
content in postmenopausal women. 
2,3 Histomorphometly, the concept of the basic multicel/u/ar unit (EMU), 
Kr0lners findings are in agreement with the increased rate of trabecular bone loss 
in women during five years following the menopause, as derived from histomor-
phometric analysis of bone from iliac crest biopsies (Meunier et a1., 1973). Histo-
morphometry of bone obtained from the iliac crest, as part of the central skeleton, 
may not only provide data on trabecular and cortical bone volume, but also on 
static and dynamic (tetracycline labelling) parameters of bone formation and 
resorption (Bordier & Tun Chot, l 972), After skeletal growth is completed, the 
mass and shape of the normal adult skeleton is determined by a process of 
balanced bone resorption and formation called remodeling. According to the 
theory of Frost, as recently reviewed by Jaworski (1981), bone formation and 
resorption are coupled in the form of so-called EMU's activated at the three bone 
envelopes: periosteal, Haversian and endosteal. Osteoclastic bone resorption at 
one site is, via a reversal phase, systematically followed by recruitment of osteo-
blasts and deposition of bone matrix. Mineralization of osteoid completes the 
remodeling cycle leaving osteocytes embedded in the calcified bone, while the 
bone surface is covered with (resting) lining cells. The activation frequency of 
BMU's in bone determines the turnover of the total skeletal mass. The balance 
between the amount of bone resorbed and formed at each of the BMU's determ-
ines whether locally, skeletal mass is gained or lost (remodeling balance). The 
change in the total amount of bone for the whole skeleton is determined by the 
sum of remodeling balances of the BMU's at the three bone envelopes, while the 
rate of change of bone mass is determined by the activation frequency of BMU's. 
On theoretical grounds a net loss of bone mass, as occurs during aging, can be the 
result of increased resorption, decreased formation or a combination of both. At 
the cellular level quantitative or qualitative changes of bone resorbing and bone 
forming cells can be responsible. An increase in bone turnover rate is initiated by 
stimulation of bone resorption, for instance by one of the regulators of bone 
mineral homeostasis as discussed later in Chapter III. In the initial phase of certain 
metabolic bone diseases, when increased bone resorption is not (yet) accompanied 
by increased bone formation, this increased "remodeling space" results in a 
temporary loss of bone mass (primary hyperparathyroidism, hyperthyroidism), 
2.4 Osteopenia and osteoporosis 
When the quantity of bone is too small for age, sex and body size, while the 
composition of its constituents is grossly normal (in the sense that there is no 
mineralization defect), the term osteopenia has been applied. Newton-John & 
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Morgan (1970) defined osteopenia arbitrarely as a bone quantity less than 2 
standard deviations below the mean value reached at maturaty. With this defini-
tion one does not take into account the physiologic bone loss with increasing age, 
or the fact that certain parts of the skeleton are more liable to lose bone than 
others, resulting in vertebral crush fractures and fractures of the ribs, forearm and 
proximal part of the femur. When, as a result of decreased resistance to stress, 
these fractures occur without a so-called adequate trauma (pathologic fractures), 
the term osteoporosis is generally used. According to Courpron et al. (1976) 
patients with pathologic vertebral fractures had histomorphometrically iliac crest 
trabecular bone volume percentage values below 11% (vertebral fracture 
threshold). 
In Table 2.1 some clinical situations are listed that may be associated with less 
than the normal amount of bone. Whether patients with so-called primary osteo-
porosis represent the lower part of a normal distribution curve, as suggested by 
Newton-John et al. (1970), or have lost and will lose bone more rapidly than 
normal people of the same age and sex (Doyle, 1972), is still a matter of debate. 
Table 2.1 
CAUSES OF OSTEOPOROSIS 
SECONDARY 
a. congenital, hereditary 
- osteogenesis imperfecta 
- homocystinuria 
- Marfan syndrome, Ehlers-Danlos 
disease 
b. endocrine 
- hyperparathyroidism* 
- hyperthyroidism* 
- glucocorticoid excess 
(endogenous or exogenous) 
- hypogonadism 
- diabetes mellitus 
c. nutritional 
- protein malnutrition 
d. gastrointestinal tract diseases 
- stomach resection 
- malabsorption syndrome 
- chronic liver disease 
e. immobilization 
f. medicinal 
- heparin 
g. hematologic diseases 
- myelomatosis 
II PRIMARY 
- juvenile (idiopathic) 
- postmenopausal deficiency of Ca, vit. 0**, vit. C 
- ethanol excess - osteoporosis of elderly people 
• Refers to the bone tissue status after successful treatment of the endocrine 
disease 
** Usually with admixture of osteomalacia 
5 

CHAPTER lll 
Regulators of Ca homeostasis and skeletal mass. 
About 99% of total body Ca ( 1300 g) and 85% of total body P (700 g) are located in 
the skeleton (Nordin, 1976). Short-term regulation of the homeostasis of both 
minerals depends upon their free-exchangeable skeletal pools, while the extraske-
letal soft tissue also is an important source ofP. In the long-term regulation of Ca 
and P homeostasis changes in activation frequency of BMU's, their activity and 
life-span and the mineralization process are involved. In this Chapter PTH and 
calcitonin (CT), as two regulators of Ca homeostasis, as well as other hormones 
and factors with a more indirect influence on bone cells and bone mineral 
metabolism will be discussed. With regard to the investigations described in this 
thesis, the activation of vitamin D and the function of vitamin Din gastrointestinal 
Ca absorption are dealt with in more detail. 
3.1 Parathyroid hormone (for review see Habener & Jacobs, 1982). 
A decrease of plasma Ca concentration within the range of 2.62- 2.25 mmol/l is 
one of the main stimuli for the secretion of PTH. It is the ionized form of Ca that 
regulates the PTH secretion. Other factors involved are magnesium, adrenergic 
agents and histamine. The secretion of PTH is inhibited by an increase in plasma 
Ca concentration. Some in vivo (perfusion studies) and in vitro (parathyroid tissue 
culture) studies point to inhibition ofPTH secretion by 1,25-(0H)2D, 25-(0H)D 
or 24,25-(0H)2D (Canterbury et aL, 1978; Dietel et aL, 1979). The evidence for 
such a short-loop regulation of PTH secretion is, however, not conclusive (Roth-
stein et aL, 1983). Glucocorticoids may also have a role in the regulation ofPTH 
secretion (see Chapter V). PTH certainly has effects on osteoblast-like cells and 
stimulation of bone formation by PTH or one of its fragments has been reported 
(Hermann-Erlee et aL, 1976; Reeve et aL, 1980"). The most striking effect ofPTH is 
stimulation of the number and activity of osteoclasts, leading to resorption of 
bone tissue and mobilization of bone mineraL Osteocytic osteolysis is possibly 
involved in short-term Ca homeostasis. PTH lowers reabsorption of P in the 
proximal renal tubule. TheCa reabsorption in the distal tubule is influenced in the 
opposite direction. PTH is an important stimulator of mitochondrial In-
hydroxylation of 25-(0H)D in the proximal renal tubular cells. Both in the 
secretory process and in some of the actions of PTH on target organs, the 
generation of cAMP is involved. 
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Secondary hyperparathyroidism (elevated PTH levels and characteristic bone 
histology) may play a role in the pathogenesis of primary osteoporosis in a 
subgroup of patients (Teitelbaum et a!., 1976). In many patients with primary 
osteoporosis normal PTH levels and PTH secretory reserve (Bouillon eta!., 1979) 
or even low basal PTH concentrations (Gallagher eta!., 1979) have been reported. 
3.2 Calcitonin (for review see Austin & Heath III, 1981). 
Hypercalcaemia is probably the most important stimulus for the secretion of CT 
by the parafollicular C-cells of the thyroid gland. Several gastrointestinal hormo-
nes and biogenic amines may also be involved in its secretion. CT inhibits bone 
resorption by decreasing the number and activity of osteoclasts and this results in a 
decreased efflux of bone minerals. The renal clearence ofCa and Pis increased by 
CT and a short-term water diuresis with increased excretion ofNa and K has been 
described. There is no agreement with regard to the effects of CT on the lex-
hydroxylation of 25-(0H)D and on intestinal absorption of Ca. CT may be 
regarded as a "bone mass sparing" hormone with elevated plasma levels during 
states of increased demands for Ca (pregnancy, lactation). Repeatedly, lower basal 
and stimulated CT levels have been found in women as compared to men of the 
same age group (Deftos eta!., 1980). 
In both sexes the secretory reserve for CT has been reported to decrease with age 
(Deftos et al., 1980, Shamonki et al., 1980). With the aid of a sensitive assay for CT 
monomers, Body & Heath Ill (1983) could confirm the above mentioned sex 
difference in basal CT and its secretion reserve, but not the age related difference. 
This could be relevant for the development of postmenopausal osteoporosis. Bone 
mass was found to be decreased in thyroidectomized patients on adequate dosage 
of thyroxine (MacDermott et al., 1983). 
3.3 Vitamin D (for review see Norman et a/., 1982; Kanis et a/., 1982; Mawer, 
1982). 
3.3.1 Production 
The third regulatory factor in bone mineral and bone mass homeostasis is activa-
ted vitamin D. At least one of its derivatives (1,25-(0H)2D) has been shown to act 
as a hormone in physiological concentrations. After photochemical conversion of 
?-dehydrocholesterol in the skin to previtamin D and isomerization to vitamin 0 3 
or cholecalciferol it is transported to the liver and hydroxylated at the c25 position. 
Bound to the same plasma protein it is subsequently delivered to the kidney, where 
it is further hydroxylated at C, or c, to 1,25-(0H)2D or 24,25-(0H)2D 
respectively. 
3.3.2 Regulation 
Several factors are involved in the regulation of these renal hydroxylases.PTH and 
low plasma levels of Ca and P stimulate the renal I a-hydroxylase. There is no 
consensus as to whether the presence of the parathyroid glands is a prerequisite for 
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'he stimulation of !a-hydroxylase by low Ca levels (Tanaka & DeLuca, 1973; 
Trechsel et a!., 1980). In patients with hypoparathyroidism low levels of 1,25-
(0H),D have been found in the presence of hypocalcaemia and normal serum P 
levels (Lund eta!., 1980). High normal concentrations ofCa, P and 1,25-(0H)2D in 
plasma inhibit the formation of 1,25-(0H),D and stimulate the 24-hydroxylase 
activity. In kidney tissue from birds the formation of I ,25-(0H),D is found to be 
increased by prolactin (Spanos et al., 1976) and estrogens (Castillo eta!., 1977). 
During- short-term administration of pharmacologic dosis of growth hormone in 
growth hormone deficient children, the plasma levels of I ,25-(0H)2D increase 
(Burnstein eta!., 1983). In man during growth, pregnancy and lactation, high 
levels of I ,25-(0H),D have been reported (Aksnes & Aarskog, 1982; Brown eta!., 
1979), but data on 1,25-(0H),D levels in patients with acromegaly or hyperprolac-
tinaemia are inconsistent (Lund eta!., 1981; Adams eta!., 1979).In patients with 
hyperthyroidism decreased serum 1,25-(0H),D and increased 24,25-(0H),D con-
centrations have been found (MacFarlane et a!., 1982; Jastrup et a!., 1982), 
probably secondary to an increased efflux of bone mineral to the plasma. 
Recently, similar changes have been reported in patients with type I diabetes 
mellitus (Frazer et al., 1981) or streptozotocin induced diabetes mellitus in rats 
(Hough eta!., 1983). A rolefor CT in the regulation of vitamin D metabolism is at 
least doubtful and the effect of glucocorticoids is reviewed in Chapter IV. 
A seasonal variation for 25-(0H)D and 24,25-(0H)2D with peak levels in late 
summer is now widely accepted. We also reported a similar seasonal variation for 
1,25-(0H),D in normal individuals studied longitudinally (Juttmann et a!., 
1981 b). With increasing age 25-(0H)D, 24,25-(0H),D (Weisman et al., 1981) and 
1,25-(0H),D (Gallagher eta!., 1979) concentrations decrease. 
Further hydroxylation of the dihydroxy-metabolites to inactive compounds 
occurs in the kidney and the intestine. Recently Ia- and/or 24-hydroxylase 
activities have been discovered in bone, placenta, mammary gland and intestine. 
3.3.3 Functions 
In view of the wide variety of tissues with cytoplasmic and nuclear receptors for 
1,25-(0H),D, vitamin D metabolites may have a large number of biological 
functions, many of which are unknown. In addition to the intestine, kidney and 
bone, these receptors are present in parathyroids, pituitary, placenta, gonads, 
mammary glands, skin and mononuclear leucocytes. 
Bone 
In physiological concentrations, vitamin D (1,25-(0H),D, but possibly also 24,25-
(0H)2D) is necessary for adequate mineralization of bone matrix (Kanis et al., 
1978). In vitro I ,25-(0H),D stimulates bone resorption and inhibits bone matrix 
synthesis (Holtrop eta!., 1981; Raisz et al., 1978). This bone mineral mobilizing 
action is important during vitamin D intoxication (Streck et al., 1979). 
Kidney 
Changes in phosphaturia and calciuria, ascribed primarily to the action of 25-
(0H)D or 1,25-(0H),D, have been reported in the literature, but conflicting data 
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may result from concomittant changes in serum levels of Ca, P or PTH. Admini-
stration of pharmacologic dosis of 25-(0H)D to thyroparathyroidectomized 
(TPTX) dogs during volume expansion raised tubular reabsorption of both Ca 
and P(Puschett et al., 1972), and 1,25-(0H)2D lowered phosphaturia and stimula-
ted tubular reabsorption ofCa in D deficient TPTX rats (Constanzo et al., 1974; 
Puschett & Kuhrman, 1978). 
Intestine 
Intestinal Ca absorption and the stimulatory activity of physiological concentra-
tions of vitamin D (especially 1,25-(0H)2D) on this process have been studied 
extensively and will be reviewed in connection with the investigations described in 
Chapters VI and VII (for reviews see Bikle et al., 1981 and Nemere & Norman, 
1982). 
Intestinal absorption of Ca can occur against a concentration gradient by an 
energy dependent process (Schachter & Rosen, 1959). The results of absorption 
studies in the small intestine of the rat and man, using varying Ca concentrations, 
are compatible with a saturable carrier mediated transport process in combination 
with a passive diffusion component (Walling & Rothman, 1969; Ewe, 1972; 
Wilkinson, 1976; Pansu et al., 1983). Thefirst mechanism is only demonstrable in 
the more proximal parts of the small intestine, it is vitamin D dependent and 
related to the high transport capacity for Ca in the duodenum. 
Kinetic data of this carrier mediated transport process, studied in the rat in vivo 
(Pansu et al., 1983), differ from those of in vitro studies with everted gut sacs, 
Ussing chambers or in vitro perfusion of intestinal segments (Walling & Rothman, 
1969 and 1973; Ewe et al., 1972). Pansu et al. (1983) reported an apparent 
half-saturation constant for the saturable component of net Ca absorption (K1) in 
rat duodenum of about 20 mM, while in in vitro experiments with rat gut K1's in 
the range of 1-2 rnM have been found (Walling & Rothman, 1973; Ewe, 1972). 
With triple lumen perfusion studies of the proximal jejunum in human volunteers 
an apparent half saturation constant of 1-5 mM for saturable Ca absorption has 
been reported by Ireland & Fordtran (1973). In the rat the net absorption ofCa in 
vivo correlates, in the more distal parts of the small intestine, with the absorption 
of fluid (Behar & Kernstein, 1976). This suggests Ca absorption by passive 
diffusion via a mechanism called "solvent drag". 
Net Ca absorption is determined by kinetics ofCa-efflux (lumen to tissue) and 
Ca-influx (tissue to lumen). In the rat ileum, studied in vitro, Ca-influx occurs 
probably exclusively via the paracellular pathway (Nellans & Kim berg, 1978). The 
distribution between cellular and paracellular components of Ca-efflux is not 
exactly known, but, in the rat, at low luminal Ca concentrations, the cellular 
pathway is probably predominant, especially in the proximal part of the small 
intestine (Nellans & Kim berg, 1979). 
The relative contribution of several parts of the total intestinal tract to the net 
Ca balance must also be taken into account. For instance in the rat the cecum and 
colon seem to be important sites of Ca absorption (Nellans & Goldsmith, 1981; 
Favus et al., !981). 
Patient factors as age, pregnancy, intestinal transit time and food composition 
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modify the net Ca absorption in the gastrointestinal tract and this occurs partly 
via influences on the activation of vitamin D. 
At a normal dietary intake ofCa the net intestinal Ca absorption, composed of 
digestive juice Ca (3 mg/kg.day) and true intestinal Ca absorption (7 mg/kg.day), 
amounts to 4 mg/kg.day. This corresponds with 25-30 percent of the dietary 
intake (Wilkinson, I 976). 
Vitamin D deficiency causes a lowering of intestinal Ca absorption, that can be 
reserved by administration of vitamin D (Nicolaysen, 1937) or one of its active 
metabolites. A few hours after the parenteral repletion of vitamin D deficient 
animals with I ,25-(0H),D3 an increase of mucosal Ca uptake and transepithelial 
Ca transport is demonstrable (Morrissey et a!., I978; Spencer eta!., !978). This 
correlates with the appearance of several intracellular proteins: calcium binding 
protein (CaBP) (Wasserman & Taylor, 1966), intestinal membrane calcium-
binding complex (IMCal) (Kowarski & Schachter, 1980) or increased enzyme 
activities: alkaline phosphatase (Norman eta!., 1970). These effects of vitamin D 
are probably receptor-mediated. There is no agreement on the time sequence of 
the events after vitamin D repletion nor on the rate limiting step in the transepithe-
lial Ca transport. One of the earliest changes is seen at the level of the luminal 
membrane: an increased Ca uptake in BBMV, prepared from vitamin D deficient 
chicks, is found within 2 hours after the in vivo administration of 1,25-(0H)20 3• 
This rise is not prevented by pretreating the animals with an inhibitor of protein 
synthesis (cycloheximide) (Rasmussen eta!., 1979). These data are in agreement 
with those ofBikle eta!. (1978), who found that the early increase in transepithelial 
Ca transport in the duodenum of vitamin D depleted rats after repletion with 
l,25-(0H)2D, was not inhibited by actinomycin D or cycloheximide. Changes in 
lipid composition and luminal membrane fluidity have been described and appear 
to be correlated with the early action of vitamin Don transepithelial Ca transport 
(Matsumoto et aL, 1981). It is not known whether this effect is specific for vitamin 
D. Ca uptake by other membranes from intestinal cells (for instance: Golgi, 
mitochondrial) is also considerably changed by vitamin D. Golgi membrane 
vesicles have a 10 fold higher Ca accumulation rate and a 3 fold higher binding 
capacity for Ca compared to BBMV (Freedman et al., 1981). Their role in 
transcellular Ca transport is not exactly known. Extrusion ofCa at the serosal side 
of the intestinal epithelial cell is an energy dependent process, in which a Ca-Na 
exchange and a Ca-ATPase are involved (Ghijssen & v.Os, !982). 
3.3.4 Vitamin D and osteoporosis 
Both normal and low serum levels of 25-(0H)D and I ,25-(0H)2D and a smaller 
rise of serum I ,25-(0H)2D after injection of exogenous PTH have been reported in 
elderly patients with osteoporosis (Slovik et al., I981; S0rensen et al., 1982; von 
Knorring et al., 1982). The same is true for the intestinal Ca absorption, which was 
found to be decreased in patients with osteoporosis of the aged (Caniggia et al., 
1963; Spencer et al., I964). However, these changes occur also during the normal 
aging process (Bullamore et al., 1970; Gallagher et al., 1979), so that their role in 
the pathophysiology (via secondary hyperparathyroidism) of primary osteoporo-
sis has not yet been established. 
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3.4 Other hormones that directly or indirectly may influence bone mass, but that are 
not primarily involved in bone mineral homeostasis are: (for review see Wallach, 
1979). 
Thyroid hormone: Bone turnover is decreased or increased respectively in hypo-
and hyperthyroidism in man and this last condition can, via an increased "remo-
deling space", lead to a reversible loss of bone mass (Kmlner et al., 1983). In vitro 
high concentrations of thyroxine are able to stimulate bone resorption {Raisz & 
Kream, 1983 ). 
Growth hormone (GH): This is the only hormone known to be able to increase the 
amount of bone in the adult. An increased cellular activity is seen in this condition 
in combination with an increased cortical thickness and a decreased number of 
trabeculae (with increased diameter). Like the effects of G H on other tissues those 
on bone tissue are probably mediated by somatomedins. 
Gonadal hormones: Both androgen and estrogen deficiency are associated with a 
rapid loss of bone mass and this may, at least for the cortical bone, be prevented by 
timely and adequate substitution (Meema et al., 1975; Lindsay et al., 1980). The 
effects of these hormones on bone tissue are probably indirect, as no androgen or 
estrogen receptors are demonstrable in bone cells. In vitro, estrogens can reduce 
the bone resorbing action ofPTH (Atkins & Peacock, 1975). 
Schlechte et al. ( 1983) recently described a decreased bone density in the distal 
part of the radius in patients withhyperprolactinaemia. The underlying pathogene-
tic mechanism is not established, but may be related to hypo-estrogenism. 
The association of long standing diabetes mellitus with osteoporosis is well-
known. In this connection the in vitro demonstrated stimulation of bone collagen 
synthesis by insulin (Raisz & Kream, 1983) may be important. The role of 
glucocorticoids in the regulation of bone mineral homeostasis and bone cell 
turnover will be discussed in Chapter IV. 
Finally, an increasing number of agents affecting bone cells locally have been 
described in in vitro studies: prostaglandins, lymfokines and local growth factors 
(Canalis, 1983"). Their role in the regulation of bone cell turnover is yet to be 
explored. 
From epidemiological surveys it appears that primary osteoporosis (post-
menopausal or of elderly people) may be associated with changes in concentra-
tions of regulators of bone mineral homeostasis and bone cell turnover. Although 
some of these factors will be causal, others are secondary. As is evident from this 
short survey, the pathogenesis of primary osteoporosis is multifactorial and in 
individual patients risk factors may be identified. Glucocorticoid induced bone 
disease is more uniform in its pathophysiology. The influence of GC excess on 
hormonal and other factors regulating bone mineral homeostasis and on their 
target organs is reviewed in more detail in Chapter IV. 
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CHAPTER IV 
Interaction between glucocorticoids, 
calcium homeostasis and bone. 
The serum calcium lowering effects of high doses GC in hypercalcaemia due to 
vitamin D intoxication (Streck et al., 1979), sarcoidosis (Bell et a!., 1979), 
malignancies, especially hematologic ones (Bentzel eta!., 1964), hyperthyroidism 
(Parfitt & Dent, 1970) and in idiopathic hypercalcaemia of infancy (Morgan et al., 
1956) indicate an interaction between GC and Ca homeostasis. In the preceding 
Chapter is outlined that regulators of bone mineral metabolism influence bone 
mass. Studying the pathogenesis ofGC induced bone disease, one should look for 
GC associated changes _in these factors as well as for direct actions ofGC on bone 
cells. 
4.1 Parathyroid hormone. 
4.1.1 Interaction with physiologic levels of GC. 
With regard to Ca homeostasis, PTH and the glucocorticoid hormones are 
antagonists, GC having a hypocalcaemic action. In rats (Williams et a!., 1974; 
Feigal & Messer, 1981) and mice (Meyer & Brinkley, 1972) the fall in serum Ca 
that occurs after (thyro)parathyroidectomy is diminished, when it is combined 
with adrenalectomy. This effect is demonstrable in the presence as well as in the 
absence of the thyroid gland. Adequate suppletion with GC leads to a further 
decrease of serum Ca, which is probably not due to increased renal loss (Feigel & 
Messer, 1981). Another example of opposing actions of PTH and GC in Ca 
homeostasis is the hypercalcaemia that is frequently seen in patients with adrenal 
insufficiency (Walser eta!., 1963; Walker & Davies, 1981). The hypercalcaemic 
action of exogenous PTH in mice is diminished by previous adrenalectomy; 
adrenalectomy does not affect the phosphaturic action of exogenous PTH in these 
animals (Meyer & Brinkley, 1972). These findings fit in the concept of a permissive 
role of GC in the normal activity of PTH in bone mineral mobilization. 
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4.!.2 Interaction ofPTH with supra physiologic levels of GC (short-term). 
Variable effects of GC excess on the parathyroid tissue have been reported. This 
variability probably depends upon the experimental conditions. Au (1976) found 
a dose related stimulatory effect on the PTH release from rat parathyroid glands 
cultured for 48 hrs in the presence of cortisol (l0-6-10-8M). Chertov et al. (1977), 
however, were unable to stimulate the PTH release from bovine parathyroid 
glands cultured with 10-5M cortisol for 36 hrs. Intravenous administration of 
hydrocortisone (200 mg/ 4 hrs) raised serum PTH levels in man without detectable 
changes in serum Ca concentrations (Fucik et al., 1975). Williams et al. (1974) and 
Kukreja et al. (1976) found increased levels ofPTH in rats treated with high doses 
of GC for I and 2 weeks, respectively. Hahn et al. ( 1980) and Zerwekh et al. (1980) 
observed no significant changes in serum PTH levels when normal volunteers were 
given 20 mg or 50 mg prednisone daily for 15 or 7 days respectively, but when 
similar doses of GC were continued for 30 days, a significant increase was found 
(Gennari et al., 1981). 
4.1.3 Interaction with supra physiologic levels of GC (long-term). 
In patients with chronic endogenous or exogenous hypercortisolism serum PTH 
levels are often found to be elevated (Fucik et al., 1975; Luker! & Adams, 1976; 
Bressot et al., 1979; Findling et al., 1982 and Suzuki et al., 1983) when compared 
with matched "eucorticoid" patients. These findings are compatible with the 
increased numbers of osteoclasis, as described by Bressot et al. (1979) and Hahn et 
al. ( l979b), in trabecular bone from patients with hypercortisolism. 
4.2 Calcitonin 
4.2.1 Interaction with physiologic levels of GC. 
Cortisol probably does not have a permissive role in the action of CT on bone 
mineral metabolism, as adrenalectomy does not influence the hypocalcaemic and 
hypophosphataemic effect of exogenous CT in mice (Meyer & Brinkley, 1972). 
The adrenals are, however, indispensable for the induction of increased renal 
secretion of water, Na and K by CT, as demonstrated by Aldred et al. (1971) in the 
rat. 
4.2.2 Interaction with supraphysiologic levels of GC. 
The hypocalcaemic effect, that is seen after injection of a standard dose of CT in 
rats, is diminished by high doses ofGC (Thompson et al., 1968). There is not much 
information on levels of serum CT during hypercortisolism. Lo Cascio et al. 
(1982) reported low serum CT levels in 7 patients treated for 2-8 months with high 
doses of GC. Thompson & Urist (1973) observed faster bone loss during exoge-
nous hypercortisolism in thyroidectomized rabbits (T4 suppleted) as compared to 
intact (not CT deficient) controls. His hypothesis of an antagonism between GC 
and CT is supported by the fact, that a lesser degree of osteoporosis was induced 
by GC in these animals when they were also treated with CT (Thompson et al., 
1972). 
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4.3 Vitamin D metabolism. 
Besides the therapeutic effect of GC in patients presenting with vitamin D 
intoxication, another example of antagonism between these two hormones is 
given by Farrell et al. (1976), who described a patient with idiopathic hypopara-
thyroidism developing, during treatment with vitamin D, a severe hypercalcaemia 
when an adrenal insufficiency supervened. Of course such an apparent antago-
nism can be indirect, resulting from a GC induced increased loss of Cain the faeces 
or in the urine. 
4.3.1 Interaction with supraphysiologic levels ofGC (short-term). 
In 1968 Avioli et al. found a decreased plasma halflife of'H-labelled vitamin 0 3, 
with the appearance of increased levels of biologically inactive metabolites in the 
plasma of volunteers, treated with prednisone for 10 days. Iri other experiments 
with vitamin D deficient rats, treated with supraphysiologic doses of GC, less 
1,25-(0H),D3 appeared to be formed from labelled precursors, while there was a 
rapid accumulation of more polar inactive metabolites (Favus et al., 1973; Carre 
eta!., 1974; Edelstein eta!., !977). However, when determinations of the vitamin 
D metabolites became available, no changes in serum levels of 1,25-(0H)2D were 
found during short-term administration of supraphysiologic doses of GC in men 
(Zerwekh eta!., 1980; Keck eta!., 1982; Gennari eta!., 1982b). Hahn eta!. (1981) 
even reported an increased concentration of 1,25-(0H),D after 14 days of predni-
sone administration (in a daily dosage of 20 mg) to 12 volunteers. This was 
accompanied by a decrease of the fractional intestinal absorption of47Ca. Spanos 
et al. (1977) found a slight stimulation of !a-hydroxylase activity in kidney 
tubules, following treatment of chickens with cortisol. 
4.3.2 Interaction with supraphysiologic levels of GC (long-term). 
During chronic hypercortisolisrn most patients have normal serum levels of 
25-(0H)D (Aloia et al., 1974; Hahn et al., 1977; Bressot eta!., 1979; Findling et al., 
1 982). For the subgroup in which decreased concentrations of this metabolite have 
been found (Klein eta!., 1977; S!ovik et al., 1980), one has to take into account the 
influence of the underlying disease for which GC have been prescribed, sunlight 
exposure, dietary factors, seasonal variation of vitamin D metabolites etc. In a few 
studies low levels of 1 ,25-(0H),D have been observed in children with renal 
disease and adolescents with lupus erythematodes, both treated with GC (Chesney 
et al., 1978; O'Regan eta!., 1979). These findings are in contradiction with the 
normal levels, production rates and metabolic clearance rates of I ,25-(0H),D 
reported by Seeman eta!. (1980), studying patients before and during treatment 
with high doses of GC, or before and after succesfull treatment of endogenous 
hypercortisolism. Nothing is known about the levels of 24,25-(0H),D in man 
during chronic GC excess. 
From these data an absolute deficiency of active vitamin D does not seem likely 
to be of predominant pathophysiologic importance in GC induced bone disease. 
In agreement with these findings osteomalacia is not a hallmark of the histology of 
glucocorticoid bone disease. In view of the negative bone mineral balance, result-
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ing from renal and gastrointestinai losses, a compensatory increase of vitamin D 
activity might be expected. As this has not been found, a relative deficiency of 
vitamin D may still be involved. 
To obtain further information on the interactions between GC and vitamin D, 
we studied the effect of short-term administration ofGC on serum concentrations 
of vitamin D metabolites in patients with different levels of parathyroid gland 
function (Chapter V). 
4.4 Influence of GC excess on other hormones. 
4.4.1 Thyroid hormones. 
Supraphysiologic doses ofGC, administered for 5 days to volunteers, induce a fall 
in serum T4 and T3 and a rise of rT3 (Gamstedt, 1981). It appears that the 
secretion ofT4 as well as the peripheral conversion ofT4 to T3 are impaired. Basal 
TSH levels in substituted hypothyroid patients fell during treatment with predni-
sone (20 mg daily for 9 days), while plasma levels of T4, T3 and TBG remained 
unchanged (Jensen et al., 1978). The possible impact of these changes in thyroid 
hormone secretion and -metabolism on GC induced bone disease is not known. 
4.4.2 Gonadal hormones. 
In high doses GC have a depressive effect on the levels of gonadal and gonadotro-
phic hormones in serum. Many data are from studies in hyperandrogenic preme-
nopausal women (Boehm et al., 1979; Rodriguez-Rigau et al., 1979) in whom even 
low doses of GC have a suppressive effect on androgen production both from 
ovaries and adrenals (Kirschner et al., 1976). Addition of dexamethasone to 
cultures of testicular tissue from hypophysectomized rats (Welsh et al., 1982) or 
rat ovarial granulosa cells (Hsueh & Erickson, 1978), induces a local inhibitory 
effect on androgen release and the aromatisation of androgens to estrogens 
respectively. In postmenopausal women circulating plasma estrogen levels are 
mainly determined by peripheral conversion of adrenal precursors. No consistent 
data are available as to possible differences in serum levels of androgens or 
estrogens between postmenopausal osteoporotic women and non-osteoporotic 
controls (Riggs et al., 1973; Manolagas et al., 1979'; Crilly et al., 1979), but there 
are indications that treatment with GC under these circumstances lowers the level 
of oestron, adrostenedione and testosterone (Crilly et al., 1979). 
4.4.3 Growth hormone. 
The stunted growth in children as well as the loss of bone mass in adults treated 
chronically with high doses of GC, are frequently ascribed to changes in growth 
hormone (GH) secretion or depletion of its tissue mediators. Both normal and 
subnormal levels of plasma GH or responses to provocative tests have been 
reported in patients with exogenous or endogenous hypercortisolism (Hartog et 
al., 1964; Frantz et al., 1964). Normal levels of serum somatomedins, determined 
with radioreceptor- or radioimmunoassay have been found in patients with 
Cushing's syndrome or exogenous hypercortisolism (Thoren et al., 1981; Gour-
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melen et al., 1982). However, somatomedin activity measured in a bioassay was 
found to be decreased (Gourmelen et al., 1982). The inhibition of growth by GC in 
children could not be overcome by the simultaneous long-term treatment with 
human GH (Morris et al., 1968). 
4.4.4 Insulin 
GC excess is associated with an insulin resistant state, characterized by hyperinsu-
linaemia and hyperglycaemia (Olefsky & Kimrnerling, 1976; Nosadini et al., 
1983). It is not known whether this state of insulin resistance also influences the 
stimulatory effect of insulin on bone collagen synthesis, which has been demon-
strated in vitro by Raisz & Kream (1983). 
4.5 Gastrointestinal calcium absorption and GC excess. 
4.5.1 Measurements in vivo. 
Though it is generally accepted that high doses of GC decrease the net intestinal· 
Ca absorption, there are only a few well documented balance studies in man that 
demonstrate an increase in faecal Ca loss (Bunim et al., 1958; Lichtwitz et al., 
1961).ln man most studies on the effects ofGC on intestinal Ca absorption have 
been performed with radioactive Ca (e.g. comparing oral with parenteral admini-
stration). When high doses (more than 40 mg prednisone-equivalent daily) are 
used for at least one week, a decreased fractional intestinal absorption ofradiocal-
cium is generally found (Klein et al., 1977; Hahn et al., 1980; Gennari et al., 1982'). 
When administered in a lower dosage or for shorter periods of time, GC have no 
or only a small influence on intestinal radiocalcium absorption (Lekkerkerker et 
al., 1970; Zerwekh et al., 1980). The disappearance ofradiocalcium from ligated 
chicken duodenal loops in situ is inhibited by the prior administration of GC in 
supraphysiologic doses. This decrease of Ca-efflux can be reversed by feeding the 
chickens a low Ca or low P diet (Fox et al., 1978), but not by a single oral dose of 
1,25-(0H),D3, given 20 hours previously (Feher & Wasserman, 1979). The same 
authors reported a concomittant decrease of mucosal Calcium Binding Protein 
and alkaline phosphatase activity. 
4.5.2 Measurements in vitro. 
Early studies of the interference of GC with transepithelial Ca transfer were 
performed with everted gut sacs, as described by Schachter et al. (1959). The 
inside-outside (I/0) ratio's for Ca, measured after one hour or longer, were 
considered representative for active transepithelial ion transport. They were found 
decreased in sacs prepared from segments of small intestine from rats that were 
treated with high doses GC for about one week (Harrison & Harrison, 1960; 
Kim berg et al., 1971). This effect was most clearly demonstrable in the proximal 
part of the small intestine and was of the same order of magnitude as the one 
obtained by vitamin D depletion. High doses of vitamin D or its active metabolite 
L25-(0H),D3 corrected the decrease of the l/0 ratio to that of non-vitamin D 
deficient animals (Williams et al., 1961; Krawitt, 1972; Carre et al., 1974). GC 
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pretreatment reduced the mucosa to serosa Ca fluxes in rat duodenum, mounted 
in Ussing chambers (Kimberg et al., 1971; Favus et al., 1973). This, combined with 
a slightly increased serosa to mucosa flux, led to a markedly depressed net Ca 
absorption. 
4.5.3 Mechanism of action 
GC have been reported to decrease the small intestinal villous height in the rat 
depending on the dose administered, the duration of treatment and the segment of 
intestine studied (Batt & Peters, 1976; Batt eta!., 1978 Ananna et al., 1979;). A 
diminution of absorptive surface could explain the reported reduction in net Ca 
absorption during GC excess. It is also possible that intestinal Ca absorption is 
decreased by GC at subcellular level. As reviewed ( 4.3), the involvement of a 
primarily decreased availability of active vitamin D metabolites during GC excess 
may be considered improbable. Downward regulation ofintestinall,25-(0H)2D 
receptors by GC is found in the mouse but not in the rat (Hirst & Feldman, 1982) 
and finally, GC could change the action of activated vitamin Data postreceptor 
level. 
Even in the absence of vitamin D,GC excess can diminish intestinal mucosal 
transfer ofCa from lumen to serosa, as shown by Favus et al. (1973) in duodenal 
mucosa of vitamin D depleted rats, mounted in an Ussing chamber. Corradino 
(1979) found that 45Ca accumulation in cultured embryonic rat duodena, where 
the vitamin D dependent Ca transport system is not yet developed, was decreased 
in a 48h culture with hydrocortisone (10-5-I0-6M). Addition of vitamin D 
prevented this decreased uptake completely. In the rat supra physiologic doses of 
GC also reduce the gastrointestinal absorption of P (Ferraro et al., 1976) and 
cations such as Sr and Fe (Kim berg eta!., !971), while the absorption ofNa, water 
and some hexoses is increased (Charney et al., 1975; Batt & Peters, 1976) in 
association with an increased Na,K -ATPase activity (Charney eta!., 1975). 
We studied the effects ofGC excess and vitamin Don Ca uptake and glucose 
transport, at the subcellar level, in BBMV from rat small intestinal epithelial cells 
and provide some preliminary data of the influence of GC on Ca absorption, 
measured in in situ ligated small intestinal loops of rats (Chapters VI and VII). 
4.6 Renal handling of calcium and phosphorus during GC excess. 
When supraphysiologic doses ofGC are administered to patients or volunteers, a 
rise of urinary Ca is observed after 1-2 weeks (Lichtwitz eta!., 1961; Wajchenberg 
eta!., 1969; Hahn eta!., 1980). Patients chronically treated with supraphysiologic 
doses of GC usually have a urinary Ca excretion in the normal range (Mira vet et 
a!., 1977; Bressot et al., 1979; Hahn et al., 1979b), but this excretion may be 
elevated when compared with that of a simultaneously studied control group 
(Adams et al., !981; Suzuki et al., 1983). In patients with Cushing's syndrome 
urinary Ca is also frequently found to be elevated (Molinatti et al., 1960; Klee-
mann et a!., 1975). Mobilization of Ca from the skeleton could, by raising the 
filtered load and inhibiting PTH secretion, result in the hypercalciuria observed in 
hypercortisolism. Also a decrease of fractional renal Ca reabsorption in 7 of 16 
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patients, studied for 1-2 weeks after the initiation of prednisone administration, 
has been described by Laake (1960). During short-term (hours) administration of 
high doses of GC in dogs (Massry et al.. 1967) or men (Lemann et al., !970) renal 
Ca handling is not changed. In contrast, phosphaturia increases under these 
circumstances in men (Rosental et al., 1982). In rats Frick et al. (1981) found a 
decrease of the maximal tubular transport of P over the glomerular filtration rate 
(TmP/GFR) to be responsible for this phenomenon, that also has been observed 
after parathyroidectomy. Turner et al. (1982) described a decreased Na dependent 
P uptake in BBMV, prepared from renal cortical tubular cells from GC treated 
rats. Increased urinary P excretion and low serum P levels are frequently found in 
patients with Cushing's syndrome (Camanni et al., 1967) or on GC treatment 
(Rosental et al., 1982). Little is known about the direct impact of such changes in P 
metabolism on bone mass. 
4.7 Influence of GC excess on skeletal tissue 
4.7.1 Histology and histomorphometry. 
The rat is not a very suitable animal model for the study of GC induced bone 
disease. Increased loss of bone only occurs with diets unbalanced for Ca and P 
(Storey, 1960). The rabbit seems to be more appropriate and administration of 
supra physiologic doses of GC for some weeks results in a marked trabecular and 
cortical porosity at both central and appendicular skeletal sites, measured with 
histomorphometry and microradiography (Epker, 1970; Duncan et al., 1973; Jee 
et al., 1981). Generally, an increased number of osteoclasts, a decreased number of 
osteoblasts or a combination of both is described. Tam et al. (1979), using double 
labelling with tetracycline, found a significantly reduced bone mineral appositio-
nal rate in rabbits, treated with hydrocortisone (2 mg/kg for l month). By 
histological and histomorphometrical examination of trabecular bone from iliac 
crest biopsies, an increased number of osteoclasts has been observed in many 
patients with hypercortisolism (Birkenhager eta!., 1967; Bressot eta!., 1979; Hahn 
et al., 1979b). In men indirect evidence for the induction of a reduced bone 
formation rate in hypercortisolism has been obtained in the form of a low mean 
wall thickness per basic multicellular unit (Birkenhager-Frenkel eta!., unpublish-
ed! results). According to Dempster et al. (1983) this is the result of a decrease in 
the active formation period of trabecular bone packets. Bone mineralization rate 
(measured by tetracycline double labelling) has also been shown to be lowered 
under these circumstances (Bressot et al., 1979). 
4.7.2 Bone cultures in vitro. 
It has to be stressed that the data reviewed here concern the bone matrix formation 
by osteoblasts rather than true bone formation in vitro. Osteoblast collagen 
synthesis, measured by means of the incorporation of 14C-proline (as 14C OH-
proline) into the collagen of bone tissue culture, is founC to be decreased by excess 
GC (Peck et al., !967; Blumenkrantz & Asboe-Hansen, 1976; Choe eta!., 1978). 
This effect is probably not specific, as the incorporation of amino acids into other 
proteins is also inhibited (Peck et al., 1967; Blumenkrantz & Asboe-Hansen, 
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1976). Similar findings have been reported with regard to the incorporation of"S 
in cartilagenous ground substance (Murata et at., 1967; Tessler & Salmon, 1975). 
Dietrich et al. (1979) des~ribed an increased incorporation of 3H-proline into 
collagen and to a lesser extent into non-collagenous proteins in foetal rat calvaria, 
cultured in the presence of high concentrations of cortisol for the first 24 hours. 
Incorporation of 3H-thymidine into DNA and of 3H-uridine into RNA were 
unchanged. In 96 hours cultures cortisol decreased all of these activities. Recently, 
the same workers found in foetal rat calvaria cultures that the early stimulation of 
collagen synthesis by GC could only be detected in the central part, after separa-
tion of the central from the periosteal part of the bone (Raisz & Kream, 1983). 
Their hypothesis that GC have a stimulatory effect on the activity of the mature 
osteoblasts, while the differentiation of periosteal precursors to osteoblasts is 
inhibited, is attractive. A similar dual effect in time, as Dietrich et al. found, is 
described for the transient stimulation by GC of alkaline phosphatase activity in 
cultured foetal rat calvaria (Canalis, l983b) or mouse cartilage (Silberman et al., 
1981 ). 
In contrast to the histological signs of increased bone resorption in bone from 
patients, exposed to high doses of GC, these substances in vitro appear to have an 
inhibitory action on the 45Ca release from prelabeled bone material. This has been 
described for the release as stimulated by PTH, prostaglandin E2, vitamin A, 
25-(0H)D, arachidonic acid and epidermal growth factor (Raisz et al., 1972; Eilon 
& Raisz, 1978; Tashjian & Levine, 1978; Sandberg et at., 1982). However, the 
resorbing action of rat peritoneal macrophages in an in vitro system, usmg 
devitalized bone particles, is enhanced by GC (Teitelbaum et at., 1981). 
4. 7.3 Interactions between GC and vitamin D and PTH at the (sub)cellular level. 
In fetal rat calvaria the existence of cytoplasmatic GC receptors has been demon-
strated by Feldman et at. (1975). Conflicting results have been reported wich 
regard to the effects ofGC on the number or stability of l,25-(0H)2D receptors in 
several species (Manolagas et at., 1979; Chen et at., 1983). 
A number of biochemical responses of bone tissue or bone cells in culture to 
PTH is changed in the presence of GC. It has repeatedly been observed that the 
cAMP release in response to PTH in cultured rat bones is augmented by dexa-
methasone or high levels of cortisol (Chen & Feldman, 1978; Hahn & Halstead, 
1979; Ng et al., 1979). Another example of GC altering the sensitivity of the target 
cell (the osteoblast) to other hormones was demonstrated by the finding that the 
PTH and 1,25-(0H)2D 3 induced inhibition of the decarboxylation of citrate is 
more pronounced when osteoblast-like bone cells from mouse calvaria are 
cultured in the presence ofGC (Wong, 1979; Wong et at., 1980). The discrepancy 
between the increased number of osteoclasts seen in the trabecular bone from 
patients with hypercortisolism and the in vitro observed inhibition by GC of the 
bone mineral mobilizing action of PTH and other factors at first sight seems 
difficult to explain. 
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Figure 4.1 Influence of glucocorticoid excess on factors involved in the regulation of bone mass. The 
data are accumulated from literature studies in man and animal, both in vivo and in vitro. How the 
various factors may influence bone cell activity is not indicated. 
4.8 The pathogenesis of glucocorticoid induced bone disease. A concept from the 
literature. 
The factors that may play a role in the pathogenesis of GC induced bone disease 
are summarized in Figure 4.1. 
There is evidence that a state of secondary hyperparathyroidism as a conse-
quence of a decreased intestinal Ca absorption and an increased renal loss of bone 
mineral is an important factor. An increased level of parathyroid gland activity is 
indicated by the elevated serum levels ofPTH that have frequently been observed 
in patients or animals during chronic exposure to supraphysiologic levels of GC. It 
is also reflected by an increased number of osteoclasts on histologic examination 
of bone biopsies. As proposed in the preceding section the induction of an altered 
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sensitivity of bone cells to bone resorbing agents like PTH and 1,25-(0H)2D may 
also be operative in the development of GC induced bone disease. Furthermore 
there are probably indirect effects of supraphysiologic doses of GC on bone 
mediated by their influence on the production of other hormonal and local 
regulators of bone cell activity. These other factors may comprise growth hor-
mone, calcitonin, local growth factors, prostaglandins etc .. By this last mechanism 
and/or by the direct depressive effect of GC on protein synthesis, a decreased 
activity (per cell) of both the bone resorbing and the bone forming cells results. 
In theory, la-hydroxylated derivatives of vitamin D could have favourable 
actions on GC induced bone disease. Administration of activated vitamin D 
results in an ample influx of Ca and P into the extracellular fluid by increasing 
intestinal absorption of both minerals. The state of secondary hyperparathy-
roidism, with increased bone resorption, will be counteracted directly by the 
vitamin D metabolites or indirectly by elevation of plasma Ca levels. It is specula-
tive whether bone formation will be stimulated under these circumstances, for 
example by an increased availability ofCa and P or by an "anabolic" action of one 
or more of the vitamin D metabolites. To further investigate these possibilities a 
double-blind, placebo-controlled trial with la-(OH)D3 was performed in patients, 
chronically treated with supra physiologic doses of GC (Chapter Vlll). 
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CHAPTERV 
Short-term effect of prednisone or 
hydrocortisone on serum 1,25-dihydroxyvitamin D 
in normal individuals and patients with hyper-
and hypoparathyroidism. 
The content of this Chapter has been published in somewhat different form: J.J. Braun, J.R. Juttmann, 
T.J. Visser and J.C. Birkenhiiger (1982). Clinical Endocrinology 17, 21-28. 
SUMMARY 
Oral administration of prednisone (30 mg/day for 9 days) to six normal indi-
viduals induced a significant rise in the concentration of serum l ,25-dihydroxy-
vitamin D (1,25-(0H),D) within 2 days. In eight patients with primary hyperpa-
rathyroidism a larger increase of l,25-(0H)2D was observed within 3 days. In 
these patients the I ,25-(0H)2D concentration remained elevated during the whole 
period of prednisone administration (8-10 days), whereas in the control group it 
had returned to basal levels or below after 9 days of prednisone administration. 
This response appeared to be dependent upon the presence of parathyroid hor-
mone (PTH) as we found no change in the (basally low) 1,25-(0H),D concentra-
tions in five patients with hypoparathyroidism during 3-4 days of prednisone 
administration (30 mg/day). In these patients vitamin D medication had been 
interrupted 3-5 days before the administration of prednisone, whereafter serum 
calcium was kept between 2.10 and 2.30 mmol/1 by means of calcium infusion. 
The response of 1,25-(0H),D to prednisone is probably not due to a stimulatory 
action of the glucocorticoids on PTH secretion, but rather to an increased 
sensitivity of the renal tubular cells to PTH. Evidence was obtained in a hypopa-
rathyroid patient in whom we studied the response of the serum 1,25-(0H)2D level 
to exogenous PTH. This response was markedly increased when PTH was injected 
during intravenous administration of hydrocortisone in a dosage scheme that was 
able to raise serum I ,25-(0H),D significantly in 8 hours in a group of six normal 
individuals. 
INTRODUCTION 
In contrast to the well-known inhibition of intestinal Ca absorption by high dose 
GC (Lichtwitz et al., 1961; Klein et al., 1977) conflicting data with regard to the 
serum levels of vitamin D metabolites have been reported in hypercortisolism. 
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A lowered concentration of 25-(0H)D has been observed by Klein et al. (1977) 
in patients on prednisone therapy, while Aloia et al. ( 1974) and Hahn et al. (1977) 
reported normal levels in patients with Cushing's syndrome or on chronic cor-
ticosteroid therapy. Under similar circumstances subnormal concentrations of 
serum l,25-(0H)2D have been reported by Chesney et aL (1978) and O'Regan et 
aL ( 1979); the earlier study concerning children with kidney disease, Altered 
metabolism of vitamin D, involving either decreased production of active vitamin 
D or increased turnover, has been described by Avioli et al. ( 1968) in man and 
Carre et aL (1974) in rats, Seeman et aL (1980) reported normal serum concentra-
tions, production and metabolic clearance rates of l,25-(0H)2D in patients with 
endogenous and exogenous hypercortisolism, Recently Zerwekh et al. (1980) and 
Hahn et aL (1981) found no significant change of 1,25-(0H),D concentrations in 
healthy volunteers taking supraphysiologic doses GC for 7-8 days, Continuing the 
administration of prednisone for 14 days Hahn found a small but significant rise of 
serum 1 ,25-(0HhD together with a fall in fractional intestinal absorption of 47Ca. 
To elucidate some of these conflicting data we studied the short-term effect of 
prednisone on the serum levels of vitamin D metabolites in healthy volunteers, 
patients with primary hyperparathyroidism (PHP) and post-operative or idiopa-
thic hypoparathyroidism (HP), We furthermore studied in two hypoparathyroid 
patients the effect of exogenous PTH alone or combined with hydrocortisone on 
1 ,25-(0HhD in serum and on the urinary excretion of inorganic phosphate and 
cAMP, 
PATIENTS AND METHODS 
Group I consisted of six healthy volunteers (two women and four men, ages 23-40 
years, numbered 1-6), Prednisone was given orally, in a dose of 30 mg/day (in 
three divided doses) for 9 days, 
Group II comprised 8 patients with PHP (patients 1-8), The clinical and bioche-
mical data together with the adenoma weights found at operation are presented in 
Table 5, L Preoperatively, 30 mg of prednisone was given per day (in three divided 
doses) for 8-10 days, 
Group IliA consisted of four patients with postoperative HP (two women and two 
men, 16-67 years, patients 1-4) and one women with idiopathic HP (aged 35 years, 
patient 5), 
Group !IlB is formed by two women, aged 27 and 51 years, with postoperative HP, 
In all hypoparathyroid patients vitamin D medication (la-(OH)D1 or dihydro-
tachysterol) was interrupted, After 2-5 days, when the serum Ca level had dropped 
to 2.0 mmol/1 or less, an intravenous infusion of Ca (as calcium glucobionate in 
dextrose 5%) was started. After stabilization of the serum Ca level between 2.10 
and 2.30 mmol/1 for 24 h the infusion ofCa was continued and in patients of group 
IliA prednisone was administered orally in a dose of 30 mg/day (three divided 
doses) for 3-4 days, During this period the serum Ca was checked regularly and the 
infusion rate adapted when necessary to maintain the level withing the range 
indicated. Before the administration of prednisone, the Ca dose needed varied 
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TABLE 5.1 
PREOPERATIVE DATA AND WEIGHTS OF PARATHYROID ADENOMAS 
IN 8 PATIENTS WITH PRIMARY HYPERPARATHYROIDISM 
patient age sex serum 
no" yrs M/F Ca p iPTH** creatinine adenoma 
clearance weight 
mmol/l mmol II ~gil ml/min mg 
48 F 2.64 0. 72 1.1 138 330 
2 52 F 2.75 o. 71 0. 7 65 1030 
3 45 M 2.75 o. 77 0.2 125 250 
4 68 F 3.04 o. 75 2. 1 84 1800 
5 62 F 2.89 0.75 0. 9 86 300 
6 64 F 2. 71 0. 90 0. 6 116 380 
7 53 F 2. 98 0. 80 1.3 106 175 
8 49 M 2. 71 0.86 0.1 135 160 
normal 2.25-2.65 0. 95-1.45 <0. 2 100-140 
range mmol/1 mmol/1 ~g/1 m!/min 
* The patient numbers correspond to those in Fig. 5. 2 
** As assayed by Dr. Bouillon (see: Methods section) 
from 275-444 mg/24h,during prednisone from 355-675 mg/24h (not significantly 
different, paired t-test). In the two patients of group HIB the effect of intravenous 
administration of 400 mg hydrocortisone (100 mg bolus followed by 300 mg in 
four hours) atone or in combination with parathyroid extract (PTE: i. v. bolus 200 
USP U, Lilly) was studied. To keep the serum P level within the normal range 
aluminium hydroxide (1.5-3.0 g/day) was administered to patient no. 5. This 
resulted in a mean P ± I SO of I ,31 ± 0.13 mmol/1. In patients 2 and 3 serum P was 
at the upper limit of normal (mean P ± I SO of 1.41 ± 0.12 and 1.35 ± 0.22 
mmol/1, respectively), while it was moderately elevated in patients I and 4 (mean 
± I SO of2.00 ± 0.09 and 1.59 ± 0.13 mmol/1, respectively. Both patients of group 
I!IB received 3.0 grams aluminium hydroxide daily and their serum P levels did 
not exceed 1.59 mmol/1 during the whole period of the study. All patients with 
post operative HP required thyroxine substitution. Their biochemical parameters 
of thyroid function were normaL When not indicated otherwise, blood samples 
were taken after overnight fasting. 
Serum and urinary Ca, P and creatinine were determined by Technicon auto-
analyzer. In the two patients of group !liB hourly urinary excretion of cAMP was 
determined by a competitive protein binding assay as described by Brown et al. 
( 1971) and the urinary P excretion during the same period was used to calculate the 
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maximal tubular P reabsorption per unit glomerular filtrate (TmP/GFR) accor-
ding to Bijvoet (1972). Serum 25-(0H)D and 24,25(0H)2D were determined by 
competitive protein binding assay after chromatography on Sephadex LH20, for 
24,25-(0H),D followed by high pressure liquid chromatography (HPLC). Serum 
1,25-(0H)2D was estimated by means of a radioimmunoassay (RIA) also after 
Sephadex LH20 chromatography and HPLC (Juttmann et al., 1981'). The antise-
rum we used (kindly donated by Dr. R. Bouillon, Louvain) recognizes 1,25-
(0H)2D3 but not the vitamin D2 derivative. All samples obtained from one 
individual were measured in the same assay. The intra- and interassay variation is 
20 and 13% respectively. Normal values ± 1 SD throughout the year for 25-
(0H)D, 24,25-(0H),D and I ,25-(0H)2D are 56± 20 nmol/1 (n = 94), 5.0 ± 2.1 
nmol/1 (n = 94) and 113 ± 30 pmol/1 (n = 20), respectively. In group I the serum 
iPTH concentrations were determined by W. Hackeng (Municipal Hospital 
"Bergweg", Rotterdam) with a RIA, as described recently (Lips et al., 1983). In 
this assay the antiserum recognizes the mid-region of the molecule. Serum iPTH 
levels in the 8 PHP patients were determined by means of a RIA that recognizes 
mainly the C-terminal fragment of the molecule (Bouillon & de Moor, 1974). In 4 
of the patients with PHP the course of vitamin D-binding protein concentrations 
in serum during prednisone administration was measured by R. Bouillon 
(Lou vain) by means of a single radial immunodiffusion technique (Bouillon et al., 
1977). 
For statistical analysis of data within one group or between groups Wilcoxon's 
matched-pairs signed-ranks test and Mann-Whitney U test were used respectively. 
The Spearman test was employed for the detection of correlations between 
parameters. This study was approved by the Medical Ethical Committee of the 
University Hospital "Dijkzigt" and informed consent was obtained from all 
participants. 
RESULTS 
In all individuals of the control group (group I) a significant rise of the serum 
1,25-(0H)2D concentration was observed within 2 days after starting the admini-
stration of prednisone. Despite continued administration of prednisone the con-
centration of 1,25-(0H)2D then declined to reach the initial values by 9 days (Fig. 
5.1). There were no consistent changes in the concentrations of serum Ca, P, 
25-(0H)D, 24,25-(0H),D or PTH in any of the control individuals. 
In the eight patients with PHP (group II) the level of 1,25-(0H)2D showed also 
an increase within 3 days after the initiation of the administration of prednisone 
(Fig 5.2). The average maximal increament (t.) was larger than observed in the 
controls 88.8 ± 35.5 and 49.1 ± 18.3 pmol/1, respectively (t. ± I SO; MWU-test 
p 0.05). In 7 of the 8 patients the 1,25-(0H),D concentration remained elevated 
during the whole period of prednisone administration. As in the control group no 
significant change in the concentrations of Ca or the other vitamin D metabolites 
was noted. The serum iPTH and the ratio of Ca to creatinine clearance had 
significantly risen after 8-10 days of prednisone administration, while serum P 
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Fig. 5.1 Serum 1,25-(0HhD concentrations in six healthy volunteers (group I) taking 30 mg prednisone/day for 9 days (hatched bar). A, individual 
curves; B, mean values± 1 SD. Significance of the difference from baseline value:** p < 0.01; * p< 0.05. Average maximal 6. ± 1 SD for 1 ,25-(0HhD: 
49.1 ± 18.3 pmol/1. 
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Fig. 5.2 Serum 1,25-(0HhD concentrations in eight patients with PHP (group II) during preoperative administration of30 mg prednisone/day for 8-IO 
days (hatched bar). A, individual curves; B, mean values± 1 SD. Significance of the difference from baseline value:** p < O.Ol. Significance of the 
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and serum Pin eight patients with PHP (group II), during administration of prednisone. Significance 
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increased above basal values from 5 days onwards (Wilcoxon p< 0.05) (Fig. 5.3). 
Serum vitamin D binding protein did not change during the whole period of 
prednisone administration in the 4 patients with PHP, studied in this respect. No 
correlation between the serum levels of iPTH, Ca and P on the one hand and 
serum I.25-(0H)2D concentrations or maxi malt. 1,25-(0H)2D during prednisone 
on the other hand was demonstrable in the two groups. In the patients with PHP 
adenoma weights did neither correlate with basal levels of 1,25-(0H)2D nor with 
the maximal 2> 1,25-(0H),D. Mean basal levels± I SD of 1,25-(0H),D did not 
differ significantly between group land II; 55.6 ± 16.7 and 81.6 ± 30.3 pmol/1, 
respectively. Serum 1,25-(0H),D concentrations in the hypoparathyroid patients 
decreased rapidly after vitamin D medication was discontinued. 
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Fig. 5.4 A, serum Ca, P and 1,25-(0HhD concentrations in a patient with idiopathic HP (patient 5) 
during the period of infusion ofCa, before and during the administration of30 mg prednisone/day for 
3 days and subsequently treated with lo:-(OHhD ( l-2p.g daily); I ,25-(0HhD 10~ pmol/1 means at the 
lower limit of detection or undetectable. 
B. individual course of the serum 1,25-(0HhD concentrations in the other four hypoparathyroid 
patients (postoperative HP) during infusion of Ca, before and during prednisone administration 
(30 mg/day for 4 days) and during subsequent reinstitution of treatment with 1a-(OH)JD (1-3 _ug 
daily). 
30 
B 
No significant rise of 1,25-(0H),D was seen during the administration of 
prednisone to patients with HP of group IliA (Fig. 5.4). Their mean basal level 
± 1 SD (24.4± 14.3 pmol/1 was significantly lower than in group I and II (MWU-
test p < 0.05). Fig. S.SA shows a marginal increase of serum 1,25-(0H)2D after the 
i.v. injection of 200 USP U of PTE on two consecutive days in one of the hypo-
parathyroid patients of group li!B. The third injection, given 15 h after the initia-
tion of a hydrocortisone infusion, did not elicit a larger response of 1,25-(0H)2D, 
although the level of the whole curve had risen. After changing the time-table 
somewhat for the other patient with HP, in such a way that the third injection of 
PTE was given during the hydrocortisone infusion, an augmented response of 
1,25-(0H),D (and of urinary cAMP as well) was seen, as compared to the effect of 
the two previous injections (Fig. 5.58 ). The decrease ofTmP/GFR appeared also 
to be larger after the third injection. Hydrocortisone alone, administered several 
months later under similar conditions, scarcely elicited an increase of serum 
1,25-(0H)2D, but lowered TmP/GFR somewhat. 
In six normal individuals infusion of hydrocortisone with the same dosage 
scheme caused a gradual rise of serum 1,25-(0H),D, which was significant 8 h 
after starting the hydrocortisone administration (data not shown). 
DISCUSSION 
The early rise in serum 1,25-(0H)2D concentration during prednisone administra-
tion found by us in normal individuals differs from the findings of Zerwekh et al. 
(1'980) and Hahn et al. (1981). After 7 days they observed no significant increase of 
the 1 ,25-(0H),D concentration, while Hahn et al. saw a late rise (after 14 days of 
GC).In our hands 1,25-(0H),D would already have fallen to normal after 9 days. 
One has of course to consider the possibility of a secondary increase after 9 days 
and the fact that Hahn et al. did not use a divided dose scheme for prednisone 
administration. Lukert et al. (1973), using silicic acid chromotography, found an 
augmented peak corresponding to 1,25-(0H)2D, in serum extracts of rats that 
were treated with 5 mg prednisone/day for 7 days. Cortisol may induce a mode-
rate increase of chicken kidney tubule I a-hydroxylase in vitro as well as in vivo 
(Spanos et al., 1977). 
The extensive and more sustained elevation of 1,25-(0H),D that we found in the 
eight patients with PHP and the absence of an increase ofthe 1,25-(0H)2D level in 
the five patients with HP during short-term prednisone administration indicate, 
that the observed response of 1,25-(0H),D to GC administration is mediated by 
PTH. 
Breslau et al. (1982), using a higher dose of prednisone (50 mg daily) and a 
chicken intestine radioreceptorassay for 1,25-(0H)2D, could not find consistent 
changes in serum 1,25-(0H)2D concentrations. These authors compared in 7 
patients with PHP over 8 days the mean values of 4 control days and those of the 
last 4 days of prednisone treatment of each patient. 
With regard to the absence of a response of 1,25-(0H),D in HP we feel it 
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Fig. 5.5 Serum 1,25~(0HhD concentration, hourly urinary cAMP excretion and TmP/GFR in 
response to i.v. administration of PTE (200 USP U) and hydrocortisone* (bolus of 100 mg followed by 
300 mg in 4 h) in two patients with postoperative HP. A, hydrocortisone administered before the third 
PTE injection. B, PTE injected during the hydrocortisone infusion. 
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unlikely, that this is due to a suppresive effect of serum P on the production ot 
1,25-(0H)2D, as in three of the five patients serum P was not elevated during the 
study. As to the kinetics 0f the changes observed in the concentration of I ,25-
(0H)2D, one has to note that our measurements during prednisone administra-
tion were performed from 1 to 2 days onwards. Parenteral administration of 
hydrocortisone in normal individuals induced an even earlier response. We have 
as yet no explanation for the much slower secondary decline of the 1,25-(0H)2D 
levels in PHP. This phenomenon indicates the need for studies oflonger duration. 
The basall,25-(0H)2D levels in the control and PHP groups, being below the 
normal range mentioned in the methods section, deserve comment. In the relati-
vely small group of individuals from which our normal values were derived (n = 
20; ten women, ten men) the average age was 31 years (range 22-43), while in eight 
patients with PHP the average age was considerably higher at 55 years (range 
45-68). Besides group size and age, other factors such as sex, nutrition and season 
(Juttmann et al., 1981 b) may have been responsible for this apparent discrepancy. 
An effect of GC on vitamin D binding protein could not be demonstrated in 
four patients with PHP and if one assumes that the early rise of serum 1,25-
(0H)2D concentrations, induced by GC, reflects a change in its renal production, 
PTH could be operative in one of the following ways: 
1. direct stimulation of PTH secretion with subsequent activation of !a-
hydroxylase by PTH; 
2. indirect stimulation of PTH secretion by GC through increased intestinal or 
renal loss of Ca; 
3. increase in the sensitivity of the PTH target organ(s) by GC; 
4. a permissive action ofPTH, involved in a direct effect ofGC on !a-hydroxy-
lase. 
Although in vivo Fucik eta!. (1975) and in vitro Au (1976) have obtained some 
evidence for mechanism 1, we observed no change in serum iPTH levels, that 
would support this concept. The rise of iPTH in group II after 8-10 days predni-
sone treatment is in agreement with results ofBreslau et al. (1982) in patients with 
PHP and Hahn et al. (1979') in normal individuals. It probably reflects a reaction 
to an increased loss of Ca (intestinal as well as renal) in hypercortisolism, as has 
been amply documented (Wajchenberg et al., 1969; Hahn et al., 1980).lt has to be 
stressed, that different RIA's were used for group I and II. This makes the 
interpretation of the absence of a rise ofiPTH in group I difficult. No changes in 
serum Ca could be found during prednisone administration in group I or II. The 
fact, however, that in our hypoparathyroid patients the amount ofCa administer-
ed intravenously needed to maintain a serum Ca level of 2.10 to 2.30 mmol/1 
tended to increase during prednisone treatment (although not significantly so), is 
in agreement with the early induction of a negative Ca balance by GC exCess. 
A direct stimulatory effect of GC on the !a-hydroxylase (without involvement 
ofPTH) is not supported by the findings in the hypoparathyroid patients in group 
IliA, while the augmented response in patients with PHP advocates against the 
role ofPTH purely as a permissive factor (mechanism 4). 
Induction by GC of an increased sensitivity of the renalla-hydroxylase activity 
to the stimulatory action of PTH might very well explain the early rise in serum 
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1,25-(0H)2D levels. This mechanism is illustrated by the results obtained in the 
patients with HP, who received a PTE injection concomitantly with a hydro-
cortisone infusion. GC appear to potentiate the PTH induced release of cAMP 
from bone culture (Chen & Feldman, 1978) and (in patients) from the kidney 
(Gennari et al., 1981). 
The transient character of the stimulation may be caused by counter-regulatory 
effects, such as the inhibition of !a-hydroxylase by 1,25-(0H),D itself, changes in 
Ca transport from and to the (renal tubular) cell or the induction of increased 
metabolism of 1 ,25-(0H)2)D. 
The (patho)physiological significance of this relatively rapid and short-lived 
stimulation of 1,25-(0H)2D production by GC is not clear. With regard to the 
pathogenesis of bone disease in chronic hypercortisolism it may reflect an (inade-
quate) adaptation to a negative bone mineral balance which, after a short course 
of prednisone at the dose level used, is known to be present. 
For references see the common reference list. 
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CHAPTER VI 
Calcium and glucose uptake in rat 
small intestinal brush border membrane vesicles: 
modulation by exogenous hypercortisolism 
and 1,25-dihydroxyvitamin D3. 
The content of this Chapter has been accepted for publication in Biochem. Biophys. Acta: 
Hans J. Braun, Jan C. Birkenhliger and Hugo R. de Jonge. 
SUMMARY 
The effect of exogenous hypercortisolism and 1 ,25-dihydroxyvitamin 0 3 on small 
intestinal calcium and glucose transport in the rat was studied at the level of brush 
border membrane vesicles generated from isolated villous cells by a freeze-thaw 
procedure. At 5.10-5M extravesicular calcium initial uptake rates in vesicles 
prepared from triamcinolone treated adult rats were decreased by 30% after 5 
days. Since calcium ionophore A23178 virtually abolished the difference in calci-
um uptake, triamcinolone appeared to affect calcium channel density or activity 
rather than intra vesicular binding capacity. Kinetic analysis showed that a de-
crease in V max of a saturable calcium transport system could entirely account for 
the diminished rate of vesicular calcium uptake. Calcium transport rates could be 
partially restored by in vivo administration of 1,25-dihydroxyvitamin 0 3 at a 
dosage which did not affect vesicular calcium uptake in control animals. Con-
versely, sodium-driven glucose accumulation in brush border vesicles from triam-
cinolone treated rats was stimulated by 50-70% after 36h and appeared insensitive 
to vitamin D. A specific triamcinolone action on the glucose carrier itself rather 
than on the driving force of the sodium gradient was indicated by (i) a similar 
stimulation of glucose transport under equilibrium exchange conditions and (ii) an 
opposite effect of triamcinolone on sodium-driven alanine transport. The triam-
cinolone induced changes in calcium and glucose uptake were not accompanied 
by a gross alteration of membrane integrity in vitro or by major alterations in 
vesicular protein composition, intra-vesicular glucose space and sucrase or alka-
line phosphatase activity. The modification of vesicular transport properties is 
discussed in relation to the vitamin D antagonized inhibition of intestinal calcium 
uptake and the stimulation of glucose absorption in response to supraphysiologic 
amounts of glucocorticoids observed in intact epithelium. 
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INTRODUCTION 
Reduction of net Ca absorption in the proximal small intestine in response to 
exogenous hypercortisolism has been documented in animals in vitro using ever-
ted gut sacs or Ussing chambers (Harrison & Harrison, 1960; Kim berg eta!., 1971; 
Krawitt, 1972). Studies, monitoring fractional intestinal uptake of radioactive 
calcium in man, showed a diminished absorption during treatment with supra-
physiologic doses ofGC (Klein eta!., 1977; Hahn eta!., 1979b). Malabsorption of 
Ca may contribute to the pathogenesis of GC induced bone disease, presumably 
by induction of a state of secondary hyperparathyroidism (Hahn el a!., 1979b). 
A major regulatory site in transepithelial Ca transport is the passive entry of 
luminal Ca across vitamin D sensitive channels in the brush border membrane 
(Rasmussen eta!., 1979 and 1982). According to the "liponomic control" hypo-
thesis the active vitamin D metabolite 1,25-dihydroxyvitamin D (1,25-(0H)2D) 
would unmask cryptic Ca channels in the 1 uminal membrane by changing the lipid 
annulus surrounding the channel. In these studies duodenal brush border mem-
brane vesicles (BBMV) have been succesfully applied as in vitro tools to discrimi-
nate vitamin D action at the luminal membrane from its potential effects on other 
epithelial components, e.g. theCa binding protein (CaBP) in the cytosol (Wasser-
man & Taylor, 1966), the basolateral Ca pump (Ghijsen & v.Os, 1982)and Na-Ca 
exchanger (Hildman et a!., 1982) or the Ca counter-transport system in Golgi 
membranes (Freedman eta!., 1981). 
In view of the apparent antagonism between 1,25-(0H)2D and GC with regard 
to transepithelial Ca absorption the possibility was considered, that GC might 
likewise interfere with Ca transport across the luminal membrane. In the present 
study the BBMV model was chosen to monitor functional changes at the brush 
border level in adult rats treated with supraphysiologic doses of GC. Effects of 
exogenous 1,25-{0H)2D3 on this model were also examined in order to clarify the 
mechanism underlying the beneficial action of vitamin D or its metabolites on 
intestinal Ca uptake in GC treated animals or patients (Krawitt, 1972; Klein eta!., 
1977; Braun et al., 1983). Na-glucose cotransport served as a marker confined 
exclusively to the luminal membrane (Hopfer et a!., 1973) and as a sensitive 
indicator of the integrity of the vesicle membrane. 
MATERIALS AND METHODS 
Materials: Triamcinolone (Kenacort® A 40) was obtained from Squibb, 1,25-
(0H)2D3 for parenteral administration was kindly provided by Hoffmann La 
Roche, phlorizin was obtained from Fluka, D-[l-3H)-glucose from NEN and 
other radioactive isotopes were obtained from the Radiochemical Centre, Amers-
ham. TheCa ionophore (A23178) was obtained from Boehringer. Other che-
micals were analytical grade. Nitrocellulose filters were obtained from Sartorius, 
The Netherlands. 
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Animals: Adult male Wistar rats weighing 300-350 gram and fed normal labora-
tory chow were injected subcutaneously (s.c.) with a suspension of triamcinolone 
acetonide (TA), sustained release, at a dosage of6 mg/kg (0.05 ml), five days prior 
to vesicle preparation (Group I!). In Group Ill this treatment was combined with 
s.c. administration of 1,25-(0H),D3, 300 ng/kg (0.05 ml), 36 and 12 hours prior to 
vesicle preparation. Group IV was pretreated with 1,25-(0H)2D3 alone and Group 
I, the control group, was injected with equivo1umes 0.9% NaCL In combined 
experiments vesicle preparations obtained from different groups were studied 
simultaneously. The existence of a state of hypercortisolism after 5 days was 
confirmed by the finding of suppressed endogenous corticosterone levels (not 
shown). For the time-effect study TA, 6 mg/kg, or 0.9% NaCI (both 0.05 ml) was 
administered s.c. 10,36 and 120 hours prior to vesicle preparation. 
Preparation of vesicles: BBMV were prepared from the proximal half of the rat 
small intestine. Intestines from 2 rats were pooled for a single vesicle preparation. 
Under light aether anaesthesia the small intestine was removed and rinsed 3 times 
with 20 ml icecold 0.9% NaCL All further steps were performed at 0-4'C First 
intestinal villous cells were released by mechanical vibration as described earlier 
(Hiilsmann et aL, 1974). Cells were collected by centrifugation (160 g, 5 min) and 
the cell pellet derived from 2 rats was washed 3 times with 40 ml buffer containing 
10 mM maleate, 300 mM mannitol and 0.02% NaN3 brought at pH 7.2 with Tris 
(buffer A). The method used forvesiculization of the brush border membrane and 
purification of BBMV will be published in full detail elsewhere. In short, the cell 
pellet was resuspended in 10 m1 buffer A and quickly frozen in liquid nitrogen. 
After 10 min the frozen suspension was thawed slowly in ice water for 60-90 
minutes. Vesiculization by mechanical homogenization (Kessler et al., 1978b; 
Hauser et aL, 1980) was completely avoided. Released brush border membranes 
were separated from other membrane fragments by differential precipitation with 
10 mM MgS04(Hauser et aL, 1980) and centrifugation (3000 g, 15 min). BBMV 
were isolated from the supernatant by a second centrifugation step (27000 g, 30 
min). The crude vesicle pellet was resuspended in 20 ml buffer (pH 7.2) containing 
10 mM Tris-maleate, 100 mM mannitol and 0.02% NaN3 (buffer B). The suspen-
sion was homogenized in a Potter-Elvehjem homogenizer and the differential 
centrifugation procedure was repeated once. The final pellet was suspended in 
Buffer B prior to use. The enrichment factor of the brush border marker enzyme 
sucrase in BBMV as compared to mucusal scrapings was 32 ± 5 (n = 10). 
Vesicular transport: Vesicular Ca uptake was determined by preincubating 50 pl of 
a BBMV suspension (25-50 l'g protein) in buffer B for I minute at 25'C, followed 
by addition of an equivolume of 0. I mM 45CaCI2 (specific activity 170-200 
dpm/pmol) in the same buffer. Transport was stopped by addition of2 ml icecold 
buffer B, followed by rapid filtration through nitrocellulose filters (pore size 0.45 
fJ.). After washing 4 times with 2 ml icecold buffer B the filter was dissolved in 5 ml 
scintillation fluid (lnstagel, Packard) and 45Ca determined in a Packard 2650 
Tricarb scintillation counter. Data were corrected for blank values obtained by 
omitting BBMV from the incubation mixture. In kinetic studies of Ca uptake, 2 
mM EGTA was included in the stopbuffer in order to reduce Ca binding to the 
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vesicle exterior, which became significant at Ca levels exceeding 0.05 mM. lml!al 
Ca influx rates were calculated from the difference in vesicular Ca uptake at two 
initial time points (15 and 60 sec) when uptake was virtually linear in time at all Ca 
concentrations tested (0.015-0.9 mM). Following preloading of the BBMV during 
3 min in the presence of 50 p,M 45CaCI2 in some experiments 45Ca efflux was studied 
by diluting the incubation mixture 40-fold with buffer B containing 2 mM EGTA 
plus or minus 10 I'M Ca ionophore followed within 0-2 min by filtration and 
washing. 
Na-dependent glucose and alanine transport into BBMV were determined 
following preincubation of the vesicle suspension (50-100 l'g protein) at 25'C for 1 
min or at 37'C for 30 min followed by 1 min 25'C. Transport was started by 
rapidly mixing a droplet of 50 1'1 BBMV suspension with an equivolume of 0.2 M 
NaSCN in buffer B containing 2.6!-'M D-[1-3H]-glucose (specific activity 3 x 10' 
dpm/pmol) or 1.0 I'M L-[2,3-3H]-alanine (specific activity 8 x 104 dpm/pmol). 
Since the dissipation rate of the trans membranal Na gradient strongly affects the 
driving force for intravesicular glucose accumulation, the activity of the glucose 
carrier was also measured under isotope equilibrium conditions, as described by 
Hopfer & Groseclose (1980). In this way gradient related driving forces are 
completely avoided and changes in labeled glucose transport reflect alterations in 
glucose carrier activity. In these experiments BBMV were preincubated in :the 
presence of0.1 mM glucose and 0.1 M NaCI in buffer B for30 min at 25"C. Isotope 
uptake was started by mixing 50 pl BBMV suspension with an equivolume of the 
preincubation medium containing 0.1 mM D-[l-3H]-glucose (specific activity 2 x 
103 dpm/pmol). In case of sodium dependent glucose uptake, transport was 
stopped at 0.1 min and in case of equilibrium exchange at 10, 20, 40 and 120 sec 
with 2 ml icecold buffer B containingO.l M NaCI and 0.5 mM phlorizin. Mixing 
and stopping were performed by means of a semiautomatic apparatus constructed 
according to Kessler eta!. (1978"). Followingf!ltration on nitrocellulose filters and 
repeated washings ( 4 times with 2 ml icecold stopbuffer) the filters were processed 
for liquid scintillation counting. Equilibrium values for 3H-glucose uptake were 
obtained after 60 min of incubation. In the isotope equilibrium exchange experi-
ments the half-time for maximal uptake of labeled glucose (tY2) was estimated by 
interpolation on plots of In ( 1- uptake/uptake,) versus time, whereby uptake,= 
tracer uptake at the indicated time points and uptake oo =uptake at equilibrium 
(cf. Hopfer & Groseclose, !980). 
Miscellaneous: Protein concentrations were determined according to Lowry et al. 
(1951). Alkaline phosphatase activity was assayed at 37'C, as described by !em-
hoff et al. ( 1970). Sucrase activity measured in 0.1% Triton X100 was determined 
according to Forstner et al. (1968). Brush border proteins were analyzed by 
sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) in principle 
according to Laemmli ( 1970). 
Statistical evaluation: Results from animal Groups I-IV obtained in one experi-
ment were statistically compared with the outcome of separate experiments by a 
two way analysis-of-variance test, utilising Tukey multiple confidence intervals. In 
experiments were only 2 groups were compared the (unpaired) Student's t-test was 
applied. 
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RESULTS 
Characterization of vesicular Ca and glucose uptake: Some of the basic features of 
the Ca uptake process in BBMV prepared by the freeze-thaw technique are 
demonstrated in Fig. 6.1 A and can be summarized as follows: 
I. Binding of Ca to the vesicle exterior following the filter washing procedure 
was apparently insignificant at the low Ca concentration (0.05 mM) in the medium 
(Ca,m) selected, since (i) I mM EGTA or 0.01 mM LaCI3 added to the washing 
buffer did not affect Ca uptake values (results not shown) and (ii) excess EGTA 
added to the vesicle exterior at 25°C started a slow release of Ca from 45Ca 
preloaded vesicles, which could be accelerated substantially by addition of theCa 
ionophore A23178 (see Fig. 6.1 A, efflux experiments); 
2. Based on an osmotically active intra vesicular glucose space of 1.46 !lllmg of 
protein (Table 6.1), equilibrium uptake ofCa at 0.05 mM Ca,m should be reached 
following transport of0.07 nmol Ca/mg protein, provided that binding to internal 
Ca binding sites and the Donnan potential (Liedtke & Hopfer, 1982) could be 
neglected. However, according to Fig. 6.1A uptake of Ca reached a 15 fold higher 
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Fig 6.1 A. Time course of Ca uptake and Ca efflux, at 50 p.M Caout by BBMV in absence (•-•. 
0-0) and presence (111-B, D-D) of Ca ionophore A23178. Release of 45Ca (0-0, D-O) was 
started by diluting samples of the incubation mixture 40-fold in the same buffer containing EGT A 
(2 mM). For experimental details see Methods. 
B. Time course of glucose uptake by BBMV in the presence (•-•) or absence (1111-111) of a NaSCN 
gradient (100 mM outside, 0 mM inside at t = 0). Equilibrium uptake was reached after 30 min of 
incubation. Curve (E-11): BBMV were preincubated in the presence of 100 mM NaSCN for 30 min 
prior to 3H-glucose addition. 
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value already at 1 min and a 30 fold higher value at 5 min, implying that virtually 
all Ca uptake reflects intra vesicular binding; 
3. Preincubation ofBBMV in the presence of theCa ionophore caused a 4-6 fold 
increase in initial rate of vesicular 45Ca uptake (Fig. 6.1 A). This level of stimulation 
was persistently seen within a broad concentration range of Caout (0.015-0.9 mM; 
data not shown). Equilibrium uptake was reached already after 5 min, about 1 h 
earlier as found for BBMV in the absence of ionophore (Fig. 6.1 A). The finding 
that equilibrium values ofCa uptake in the absence or presence ofionophore were 
not significantly different, suggests that the ionophore acts on the same class of 
vesicles responsible for basal Ca transport. Since the ionophore merely increases 
the rate of Ca influx across the vesicle membrane, without affecting Ca binding 
sites, Ca entry into the vesicle interior apparently functions as a rate limiting step 
in theCa uptake process, at least during the first few minutes. Therefore initial 
rates of vesicular 45Ca uptake will primarily reflect the kinetic properties of Ca 
channels embedded in the microvillous membrane. 
Na-driven glucose accumulation increased linearly with time for about 6 sec 
(Fig. 6.1 8). At this point the "overshoot" above the equilibrium values was 15-18 
fold, a value similar to or better than reported for other BBMV preparations 
(Hopfer et al., 1973; Kessler et al., 1978b). Glucose overshoot was completely 
abolished if ionic gradients were dissipated by preincubating BBMV with NaSCN 
(0.1 M) for 30 min prior to 3H-glucose addition (Fig. 6.1 8). The glucose "over-
shoot", reflecting the activity of the Na glucose carrier, is also a sensitive indicator 
of the integrity of the vesicle membrane. Monitoring vesicle stability was conside-
red essential, because in initial experiments using BBMV prepared according to 
Kessler et al. (1978b), we noticed a variable loss of glucose overshoot during in 
vitro incubation parallelled by increased 45Ca uptake and proteolysis of intra ve-
sicular proteins, e.g. actin (data not shown). These in vitro artifacts were rarely 
seen in vesicles prepared from TA treated rats. By using the "freeze-thaw" 
procedure for vesicle isolation however, such artifacts were completely avoided. 
This is illustrated by the persistently high levels of glucose overshoot in vesicles 
from group I and II upon preincubation for 30 min at 37°C (Table 6.1). 
Changes in vesicular Ca and glucose uptake induced by GC and 1,25-(0H)2D3 : Five 
days after injection ofT A we found a significant fall in the initial Ca uptake rates 
(average 30%) in BBMV isolated from proximal small intestine compared to the 
same preparation from saline-injected rats (c.f. group II versus group I in Table 
6.1). Addition of Ca ionophore A23178 virtually eliminated any difference inCa 
uptake (measured at t = 5 min) between all four groups (Table 6.1). Since at least 
95% of total Ca uptake at 5 min reflects binding to intra vesicular receptor sites, the 
TA effect is unlikely to be the consequence of a change in intra vesicular free Ca 
space. Moreover the osmotically active intra vesicular glucose space was unaltered 
by TA treatment (Table 6.1). This table additionally shows that treatment of rats 
with 1 ,25-(0H),D3 alone (Group IV) had no influence on vesicular Ca uptake rate 
compared to controls (group I). In contrast administration of the vitamin 0 3 
derivative toT A treated rats partially counteracted theTA induced depression of 
vesicular Ca transport (c.f. Group lll versus II). 
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TABLE 6.1 TRANSPORT RATES OF CALCIUM, GLUCOSE AND ALANINE AND ACTIVITIES OF 
BRUSH BORDER ENZYMES IN BBMV FROM TA AND 1,25-(0H)2D3 TREATED RATS 
Anima! groups 
triamcinolone treated 
1,25-(0H} 2D3 treated 
Ca uptake (initial rate) a 
Ca uptake ( 5 min) a 
- ionophore 
+ ionophore 
glucose transport { NaSCN gradient) a 
preincubation min, 25°C 
preincubation 30 min, 37°C 
glucose transportb 
{tt under isotope equilibrium conditions) 
alanine transport (NaSCN gradient)b 
intravesicular glucose spaceb 
sucrase activityc 
alkaline phosphatase activitya 
o. 9.7 ± 0.25 
2.44 ± 0.44 
4.87 ± 0.62 
27. 2 ± 8. 8 
29.0 ± 14.0 
7. 8 ± 2. 1 
5.61 ± 1.27 
1.46 ± 0,15 
2. 40 ± 0. 51 
3. 74 ± 1. 27 
a mean values ± SO ( n=6); b: mean values ± SO ( n=3}; c: 
s gnificance of the difference (two way analysis of variance): 
s gnificance of the difference (Student's t-test) 
II 
•· 
nmol.min- 1 .mg 
0.68 :1:; 0.20* 
Ill 
' 
. -1 protem 
0.88 ± 0.16° 
nmol. mg protein -l 
1.74 ± 0.38* 2.17 ± 0.33° 
3. 92 ± 0. 79 4.03± 0.96 
-1 -1 pmol. 0.1min .mg protein 
45.9 ± 15.7 * 
42.8 ± 16.0 * 
3.1 ± 1.0 
sec 
55.4 ± 11.8 * 
53.4 ± 16.6 * 
n.d. 
pmol. 0. lmin 1 • mg protein 
3.26 ± 0.75 8 n.d. 
]11. mg protein 
1.48 ± 0.07 1. 40 ± 0.11 
U. mg protein 1 
2.65± 0.65 2. 70 ± 0.49 
mU. mg protein - 1 
3. 27 ± 1. 52 4. 53 ± 1. 74 
IV 
0,93 ± o. 25 
2.53 ± 0.39 
4.89 ± 0.48 
34.8 ± 7.8 
38.4 ± 8.1 
n.d. 
n.d. 
1.47± 0.09 
2.44± 0.55 
5.85 ± 2.04* 
mean values ± SO (n=4); 
*from Group I (p<O. 05); 
•from Group I (p<0.05} 
n.d.: not determined 
0 from Croup II (p<O, OS) 
Table 6.1 also shows a 1.7 fold increase of Na-dependent glucose uptake in 
BBMV from TA treated animals. Interestingly, this stimulatory effect of TA on 
glucose transport was not counteracted by 1,25-(0H),D3, but even showed a 
tendency to increase further (Group lll versus II). An opposite effect ofT A was 
found on the half filling time (tV,) for vesicular glucose uptake, measured under 
isotope equilibrium exchange conditions (Table 6.1), indicating that theTA 
induced increase in glucose uptake was the consequence of a change in glucose 
carrier activity rather than of a fall in Na permeability of the vesicle membrane. 
Moreover, Na-driven alanine accumulation was significantly depressed in BB~vfV 
from TA treated rats as compared to control vesicles (Table 6.1). 
Changes in vesicular Ca and Na-driven glucose transport were also studied at 
several time points following a single injection of saline or TA (Fig. 6.2). 
Significant changes in Na-driven glucose transport rates in TA rats were detect-
able as early as 36h, whereas a depression ofCa uptake became significant only at 
120h after injection ofT A. 
Effects ofT A and I, 25-(0H),D3 on other properties of BBMV: Table 6.1 additionally 
shows that the specific activity of the brush border membrane marker enzyme 
sucrase was not significantly different in BBMV isolated from animal Groups 
I-IV. The activity of alkaline phosphatase was also unaffected in TA treated rats. 
As expected (Norman et al., 1970), 1,25-(0H)20 3 significantly increased the 
activity of this enzyme (Group IV). As a trivial explanation for theTA effects on 
Ca and glucose transport it was also considered possible that TA treatment could 
lead to the generation or selection of a different class of vesicles no longer 
representative of BBMV. Therefore, we analyzed the protein composition of 
D 80 4 Lill 
~ 
~-
'c 
' ·;; 
* c 0 60 * 3 "2 • c 
"' "-
0 
ro 2 c c. 0> • "-, E c 0> 
' 
' 
40 2 • E • "' ~ • c • 0 
•• c. c u , 
" •• tJ 0 ' 20 ro u 0 
0 E 
E c 
"-
0 0 
10h 36h 120h 
Fig. 6.2 Effect ofT A injection on glucose and Ca transport in BBMV. Na-dependent glucose transport 
was measured at t = 0.1 min as indicated in Fig. 6.1 8 . Initial Ca uptake rates were measured at 50 ,uM 
Caout as described in Methods. Rats were killed at 10,36 and 120h following injection ofT A. Mean 
values± I SD (n = 6) are presented. The difference from controls was significant for glucose transport 
at t = 36 and 120 h: * p < 0.05 and for Ca transport at t = 120 h: * p < 0.05 (Student's Hest). 
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vesicles obtained from all groups (I-IV) by SDS-PAGE. Although changes in 
minor protein components cannot be detected accurately by this technique, the 
overall protein composition appeared very similar (results not shown). 
Effects of TA on kinetic properties of vesicular Ca and glucose transport: The 
decrease of initial Ca uptake rate in BBMV from rats treated with TA for 5 days 
was persistently found within a broad range of extra vesicular Ca concentrations 
(0.15-0.9 mM; Fig. 6.3). Analysis of the data of 4 consecutive experiments in an 
Eadie-Hofstee plot (Fig. 6.3, inset) indicated that the decrease of Ca uptake in 
BBMV resulted from a sharp decrease in the apparent V m"' (mean± SEM: 4. 7 ± 
0.6 for control versus 2.3 ± 0.05 nmol.min-'.mg protein-' for TA), predominat-
ing the effects of a decrease in the Km value of the transport system (mean± SEM: 
138 ± 4.8 for control versus 78 ± 4.81'M for TA). 
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Fig. 6.3 Initial Ca uptake rates (Vj) as a function of extra vesicular Ca concentration (Ca0 u1) in BBMV 
from control (0-0) and TA pretreated (•-•) rats. Mean values± SEM are shovm (n = 4). The 
difference from controls was significant over the whole range of Caout measured (p < 0.05, Students 
t-test). An Eadie-Hofstee plot of these data is shown in the inset. The rvalue for control and T A vesicles 
amounted to 0.99 and 0.93 respectively (Linear regression analysis). 
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Measurements of Na-driven 3H-glucose accumulation at 6 sec as a function of 
extravesicular glucose concentration and analysis of the data in a Lineweaver-Birk 
plot suggested, that TA treatment shifted the apparent V m" of glucose transport 
from 1.1 to 1.7 nmol. 0.01 min-'.mg protein-' without affecting the Km (approxi-
mately 80 I'M; data not shown). A similar Km value has been reported for the 
Na-glucose symport in renal BBMV (Aronson & Sacktor, 1975). 
DISCUSSION 
The 30% decrease inCa uptake rate found in BBMV from rats treated with GC 
could be due to a change inCa channel properties, an alteration of the number or 
affinity of intravesicular Ca binding sites or both. The finding that the Ca 
ionophore A23178, which increases theCa permeability of the vesicle membrane 
but does not affect intra vesicular Ca buffering systems, eliminated the difference 
inCa uptake between control and TA vesicles, is strongly in favour of a TA effect 
on transmembrane Ca transport rather than on intra vesicular Ca binding. Kinetic 
analysis of the Ca transport data showed that the TA induced depression of 
vesicular Ca uptake could be ascribed completely to a fall in apparent V max oft he 
Ca transport system, which is only partially compensated by a concomittant 
decrease in Km. The effect is unlikely to result from a general membrane stabilizing 
action of GC preventing in vitro breakdown of the membrane barrier (Weissman 
& Thomas, 1963), since the BBMV prepared by the freeze-thaw method were 
extremely stable as appeared from the persistence of the glucose "overshoot" 
phenomenon upon prolonged incubation at 37'C (Table 6.1). The lower level of 
vesicular Ca transport found in TA treated rats corresponds to reported effects of 
GC on intact intestinal segments in vitro (Harrison & Harrison, 1960; Kim berg et 
al., 1971). A partial restoration ofGC suppressed Ca transport by concomittant 
treatment with vitamin D or la-hydroxylated vitamin D has also been observed 
with intact intestinal epithelium both in vitro (Krawitt, 1972) and in vivo (Fox et 
al., 1978). Our finding of a 1,25-(0H)2D 3 correctable depression of vesicular Ca 
transport is not in contradiction with recent data from Schultz et al. (1982), who 
found a normal increase of Ca uptake in BBMV from vitamin D depleted chicks 
treated with GC upon repletion with 1 ,25-(0H),D3• Unfortunately, these authors 
did not present data of GC effects on BBMV from untreated normal chicks and 
they confined the period of treatment to 48h. 
Although the results of the BBMV experiments offer a plausible explanation for 
the apparent decrease in segmental intestinal Ca absorption induced by hypercor-
tisolism and for the partial reversal of this decrease by vitamin D, they do not rule 
out additional effects of GC on other parts of the transmucosal Ca transport 
system, e.g. on Ca binding to cytosolic proteins, Ca-pump activity or Ca-Na 
exchange at the basolateral membrane or on paracellular Ca transport. 
The molecular mechanism involved in GC action on theCa transport system in 
the intestinal brush border is not established by the present study. Depression of 
vitamin D activation by TA or stimulation of its catabolism are unlikely in view of 
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the normal or even increased 1,25-(0H),D serum levels found in rat (Lukert et al., 
1973) and men (Braun et al., !982) during short-term hypercortisolism. However, 
those findings do not exclude changes in intracellular 1,25-(0H),D receptor 
concentrations (Hirst & Feldman, 1982) or post-receptor events such as the 
production of cytosolic CaBP (Feher & Wasserman, 1979). A local effect ofGC in 
the villous cells, mediated by binding to steroid receptors and affecting either a 
"liponomic control" mechanism of theCa channel ( cf. Rasmussen et al., 1982) or 
the synthesis and incorporation of Ca channels into the brush border membrane, 
appears also unlikely in view of the rather slow response of the Ca transport 
system to exogenous hypercortisolism, significant only after 5 days. In contrast 
such a local mechanism could certainly play a role in the stimulation of vesicular 
glucose transport measured at 36h following TA injection. Moreover, ifGC would 
exert their action exclusively on intestinal crypt cells, implying a lag phase in the 
effects on villous cell membranes, one should expect a maximal effect on microvil-
lar Ca transport not earlier than 2-3 days after TA injection, corresponding with 
the transit time of enterocytes from crypt to villous tip (Hughes et al., 1958). We 
therefore suggest that the inhibitory action ofT A on Ca transport either originates 
in the intestinal crypt cell or is secondary to effects ofT A on non-intestinal tissues. 
The stimulation of glucose transport in response to GC at the level of BBMV 
has not been reported earlier, but seems to correspond in time with the GC 
induced stimulation of glucose absorption reported for intact intestinal segments 
(Charney et al., 1975). Charney et al. have suggested a positive correlation between 
the activation ofNa,K-A TPase in the basolateral membrane of the enterocyte and 
Na, water and glucose absorption by the intact epithelium. Since BBMV are 
devoid of this enzyme and depleted of endogenous ATP (unpublished results), 
such a mechanism cannot play a role in the stimulation of glucose transport at the 
vesicle level. On the other hand it is more plausible to explain the increased 
transmucosal glucos.e transport, observed in intact epithelium, by a GC mediated 
increase of glucose carrier activity in the brush border membrane, since this system 
seems to function as the rate-limiting step in overall-glucose transport (Sellin & 
Field, 1981 ). 
In conclusion. the results of our vesicle studies indicate that exogenous hyper-
cortisolism exerts a stimulatory effect on the Na-symport carrier for glucose in the 
brush border membrane at 36h, followed later (120h) by an inhibitory effect on the 
Ca permeability of the membrane. The active vitamin D metabolite 1,25-(0H)20 3 
was found capable to counteract the GC effect on Ca transport but not on glucose 
transport. The specific effects ofGC on intestinal brush border components not 
only form an interesting basis for further studies regarding the molecular mecha-
nism underlying GC action, but are also of clinical importance. 
For references see the common reference list. 
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CHAPTER VII 
(Addendum to Chapter VI) 
Influence of triamcinolone on calcium and water 
absorption in rat small intestinal loops in situ. 
INTRODUCTION 
Most studies demonstrating depression of net mucosal to serosal intestinal Ca 
transport in the rat by GC have been performed with isolated everted sacs of the 
proximal intestine (cf. Schachter & Rosen, 1959) or with unstripped mucosa 
mounted in Ussing chambers (cf. Walling & Rothman, 1969), In vivo however, 
Clark et aL (1959) found no changes in combined gastrointestinal and faecal 
recovery or oral 45Ca loadings in rats treated with high doses of GC and Ferretti et 
aL (1978) even observed an increased net Ca absorption, as measured by Ca 
balance: in rats with doses of cortisol roughly equivalent to those used in our 
experiments; increasing the doses of GC caused a gradual elevation of endogenous 
Ca secretion until at extremely high doses (?32 mg cortisoVkglday) the net 
intestinal Ca balance became negative. 
It seemed important to compare the results of the vesicle experiments reported 
in Chapter VI with Ca transport measurements in intact intestinal segments of rats 
subjected to the same GC regimen, using an in situ loop technique, Thus the 
contribution ofparacellular pathways to overall Ca transport and the effect of the 
so-called unstirred layer on transport rates can be taken into account. Further-
more artifacts induced by in vitro conditions (e.g. tissue hypoxia) are herewith 
avoided. Some preliminary data are reported. 
MATERIALS AND METHODS 
"CaCl2 (10-40 mCi/mg Ca) was obtained from Amersham and [1,2-3H] poly-
ethyleneglycol (PEG, MW 4000; 0.5-2 mCi/g) was obtained from NEN. 
Male Wistar rats of similar age and weight as used in the vesicle experiments 
received a s.c. injection oftriamcinolone-acetonide (TA), long-acting suspension, 
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6 mg/kg, or saline 5 days before the transport study. Absorption of fluid, 40Ca and 
45Ca was assessed in 6 rats from each group (non-fasted state) by means of a 
modification of the in situ loop technique described by Zornitzer and Bronner 
(1971). Under light aether anaesthesia the peritoneal cavity was opened and the 
whole small intestine was flushed 2 times with 20 ml isotonic saline kept at 37'C. 
Residual saline was largely removed by gently stripping the intestine between 
fingertips. Subsequently 3 segments of about 15 em each were ligated: a proximal 
jejunal loop just distal to the ligament of Treitz, a distal jejunal loop from 30 em 
distal to the ligament ofTreitz and the terminall5 em of the ileum. A control and 
TA treated rat were always studied simultaneously. One ml of transport medium, 
prewarmed to 37°, was injected by means of a syringe with a 18 gauge needle in 
each ligated segment. The transport medium contained 164 mM NaCl, 0.88 mM 
45CaCI2 (610 -680 dpm/nmol) and [1,2-3H) polyethyleneglycol (720 dpm/nmol). 
Following an equilibration period of 5 min a 10 1'1 sample from the luminal 
content was taken by means of a transmural puncture, enabling us to calculate the 
initial intra-luminal solvent volume and 45Ca content. The sample was dissolved in 
5 ml scintillation fluid (lnstagel, Packard) and 45Ca and 3H were determined in a 
Packard 2650 Tricarb scintillation counter. After 30 min the loop was removed, its 
length measured and a 10 p,l sample was again taken from the luminal content for 
determination of 45Ca and 3H radioactivity. Also the 40Ca concentration in the 
luminal fluid was determined by means of EGTA titration of a fluorescent Ca-
calceine complex, a modification of the method described by Wallach & Steck 
(1963). Finally, the excised loop was flushed with 20 ml icecold saline and 
dissolved during48 hrs in 3 ml soluene (Packard) at 600C. The extract was diluted 
12.5 fold and a I ml sample was counted for 45Ca and 3H. For determination of the 
45Ca uptake into the intestinal wall a correction for the amount of45Ca associated 
with the " 3H PEG-space" was applied. The following absorption parameters were 
determined and calculated according to Wasserman et al. (1961). 
1. Solvent absorption (Asolv.: ,ul fluid per em intestine per 30 min) defined as the 
total amount of fluid absorbed from the intestinal lumen into the tissue 
V- V, A - ' solv.---L- V,-PRx V, h b , w ere y L 
V; (initial volume in 1'1) refers to the injected solvent volume corrected for dilution 
by residual endogenous luminal fluid at t0 on the basis of the change in PEG 
concentration in the previous 5 minutes. 
v, (final volume in 1'0 refers to solvent volume left at the end of the absorption 
period (t30). This parameter is calculated as the product ofPR and V,. 
PR (PEG ratio) refers to the ratio of PEG concentration at t0 versus t30• 
L (length in em) refers to the length of the ligated intestinal loop. 
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2. Ca-efjlux (nmol Caper em intestine per 30 min) is defined as the unidirectional 
movement of calcium from the intestinal lumen to tissue (mean value over the 
period studied). 
V (45Ca) V (45Ca) Ca-efflux = ' ' - r r , whereby 
SA,+ SA, L 
2 
45Cai and 45Car (dpm per , .. d intraluminal fluid) refer to the initial and final 45Ca 
concentration at t 0 and t30 , respectively. 
SA, and SAr (dpm per nmol Ca) refer to specific activity of Ca at t0 and t30 , 
respectively. 
3. Net Ca absorption (Net Ca abs.: nmol Caper em intestine per 30 min) defined as 
the total amount of Ca absorbed from the intestinal lumen. 
Net Ca abs. = 880- 40CarVr, whereby 
880 refers to the total amount of 40Ca (nmoles) administered at t0 • 
40Car (nmol per ,ul intraluminal fluid) refers to the final 4°Ca concentration at t 30 . 
4. Ca-injlux (nmol Ca per em intestine per 30 min) defined as unidirectional 
movement of calcium that enters the intestinal lumen from the tissue. 
Ca-influx = Ca-efflux- Net Ca abs. 
In these calculations it is assumed that backflux of 45Ca from mucosa into the 
lumen is negligible. For statistical analysis Student's t-test (unpaired) and linear 
regression analysis were employed. 
RESULTS 
The treatment with TA induced a significant increase of the solvent absorption in 
each segment (Fig. 7.1). As illustrated in Fig. 7.2 this solvent uptake was correlated 
positively with Ca-efflux at the level of the proximal jejunum in the control as well 
as in theTA treated animals (r = 0.91 and 0.96, respectively).ln the distal jejunum 
and the terminal ileum this applied only to theTA treated animals (r = 0.95 and 
0.82, respectively; data not shown). Although theCa-efflux was higher at the level 
of the proximal and distal jejunum ofT A treated rats as compared to controls, the 
net absorption of Ca was decreased along the whole length of the small intestine as 
a consequence of an increased Ca secretion (Ca-influx), which was most pro-
nounced in the distal jejunal and ileal segments (Fig. 7.3). The net gain of radio-
active Ca in the intestinal tissue (corrected for 45Ca in the adhering fluid as 
quantified by 3H-PEG measurements) was not influenced by TA treatment (data 
not shown). This means that theTA induced efflux of45Ca from the lumen into the 
gut wall is exactly compensated by an enhanced flux of the tracer from the 
intestinal wall into the body. 
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Figure 7.1 Influence of TA treatment (studied 5 days after s.c. injection of 2 mg TA) on the solvent 
absorption in rat proximal jejunum, distal jejunum and terminal ileum. The mean value for each group 
is presented by a horizontal bar. 
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Figure 7.2 Correlation between solvent absorption and unidirectional Ca-efflux from proximal 
jejunum in control and T A treated rats. Linear regression: for control group: y = 1.3 x-13 (r = 0.91; 
p < 0.05) and for TA group: y = 1.2 x-10 (r = 0.96; p< 0.01). 
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Figure 7.3 Influence ofT A treatment (studied 5 days after s.c. injection of2 mgT A) on unidirectional 
Cat-efflux and net Ca absorption in rat proximal jejunum, distal jejunum and terminal ileum. Mean 
values'± I SD are presented. Differences between control and TA treated animals: * p < 0.05; 
** p<O.Ol. 
DISCUSSION 
Based on the 30% fall inCa permeability of the brush border membrane observed 
in BBMV isolated from the proximal half of the rat small intestine, following a 
similar pretreatment with TA (see Chapter VI), a decrease of Ca-efflux (lumen to 
tissue) was also expected in theCa transport experiments with in situ ligated loops. 
Paradoxically, the in situ experiments showed a significant increase of lumen to 
tissue Ca-efflux. At least two explanations for this apparent discrepancy seem 
plausible: (I) GC may exert a different effect on Ca extrusion across the basolater-
al membrane of the enterocyte, e.g. by stimulating theCa pump. This will result in 
a decrease of the steady-state level of intracellular Ca and a rise inCa entry into the 
enterocyte across the brush border (due to a steeper Ca gradient), which may 
amply compensate for the apparent decrease in Ca-channel density measured in 
BBMV; (2) in the in situ experiments increased "solvent drag" of Ca through a 
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paracellular route may mask a decrease of Ca-absorption through the micro-
villous membrane. The positive correlation found between Ca-efflux and solvent 
absorption provides strong evidence for this second hypothesis. Transepithelial 
transport of cations by such a mechanism seems especially important in the more 
distal parts of the small intestine (Behar & Kernstein, 1976). More data on the in 
vivo contributions of cellular and paracellular pathways in theCa transport across 
the intestinal wall are needed. It is probable, that the transcellular route pre-
dominates in the duodenum where vitamin D exerts its main action. 
Using in situ loop techniques similar to ours, Feher & Wasserman (1979)found 
a marked decrease of duodenal 45Ca absorption in growing chicks after two days 
treatment with cortisol (2 mg daily i.m.) and Fox et al. (1978) reported similar 
results in chickens after oral administration ofbetamethasone (251'g/kg/day) for 
14 days. These two studies differ from our experimental set-up in several respects. 
(l) Both investigations were carried out with duodenum only, which amplifies 
possible effects of GC on vitamin D dependent Ca transport. (2) The chicken is far 
more sensitive to vitamin D deprivation than the rat. (3) Fox et al. used a much 
lower dose of GC than we used in our experiments. 
The decrease in net Ca absorption by GC found in our in situ loop experiments 
results predominantly from an increased Ca secretion. The question arises as to 
the nature of the driving force involved in this process. High doses ofGC stimulate 
the transepithelial movement ofNa by enhancement ofNa,K-ATPase (Charney et 
al., 1975) and/or brush border Na permeability (Sellin & Field, 1981). The increas-
ed pumping of Na leads to hyperpolarisation of the intestinal mucosa (the 
potential difference between mucosa and serosa becomes more negative). The 
magnitude of this effect increases from the proximal to the distal part of the small 
intestine (Charney et al., 1975). Thus a driving force for the secretion of cations 
such as Ca is created, which increases from duodenum to ileum. 
In the calculation of Ca absorption from in situ ligated small intestinal loops 
possible changes in the specific activity resulting from 4°Ca secretion were neglect-
ed by Ewe (1972). He found a decreased 45Ca absorption from in situ ligated 
proximal jejunal loops of adult rats treated with high doses of GC (2 mg methyl-
prednisolone daily) for 6 days, i.e. with doses considerably higher than used in our 
study. 
The increased small intestinal Ca secretion provoked by GC may provide an 
important contribution to the total intestinal Ca balance. However, the effect of 
GC on Ca absorption in the large intestine also has to be taken into account. Kn 
Ussing chamber experiments the rat caecum and colon appeared to be effective 
sites of Ca absorption (Nellans et al., 1981; Favus et al., 1981). With the same 
technique Lee (1983) found an increased net Ca-flux in the distal colon of rats 
pretreated with GC for 4 days. 
The effect ofGC and active vitamin D metabolites, alone or in combination, on 
the absorption of Ca have yet to be studied in situ along the whole length of the 
intestine. In these studies the contribution of cellular and paracellular fluxes 
should be determined separately, in order to elucidate the mechanism underlying 
the beneficial effect of active vitamin D metabolites on intestinal Ca absorption in 
patients treated with GC (Chapters VIII and IX). 
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CONCLUSIONS 
In in situ ligated small intestinal loops of rats pretreated with GC we have found a 
decreased net Ca absorption. This was the result of a marked stimulation of theCa 
secretion (along the whole intestinal length tested) which was greater than the 
stimulation of the Ca-efflux from the proximal and distal jejunum. The relative 
contribution of the trans- and paracellular pathway in this process is unknown, 
but it seems plausible that effects of GC on the paracellular route play an 
important role in the net transepithelial Ca absorption in vivo. The use ofBBMV 
is therefore an important tool to examen GC and vitamin D effects on Ca 
transport across the microvillus without interference of possible effects on the 
paracellular route (Chapter VI). 
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CHAPTER VII! 
Influence of la-(OH)D3 administration 
on bone and bone mineral metabolism in patients 
on chronic glucocorticoid treatment; 
a double-blind controlled study. 
The contents of this Chapter have been published: 
J.J. Braun, D.H. Birkenhager-Frenkel, A.H. Rietveld, J.R. Juttmann, T.J. Visser and J.C. Birken-
hager (1983) Clin. Endocrinol. 18, 265-273. The figures 8.1-8.4 have been added. 
SUMMARY 
We have performed a double-blind placebo controlled study of !a-hydroxy-
vitamin D 3 (la-(OH)D3) 21'gdailyfor 6 months, in 14 patients receiving long-term 
glucocorticoid treatment. Patients were matched for age, sex, underlying disease 
and dose of glucocorticoid. 
Initial values for serum calcium, phosphorus and alkaline phosphatase were in 
the normal range. Two of the 14 patients showed an increased serum immuno-
reactive parathyroid hormone (iPTH) concentration. Serum 25-hydroxyvitamin 
D and 1,25-dihydroxyvitamin D (1,25-(0H)2D) were normal but the average 
24,25-dihydroxyvitamin D (24,25-(0H),D) was low. 
The histomorphometrically determined trabecular bone volume of an iliac crest 
biopsy appeared to be low in 6 patients. The average active bone resorption and 
osteoid seams were increased, while the average osteoblast seams were within the 
normal range. Treatment with la-(OH)D3 raised 47Ca intestinal absorption and 
24h urinary Ca excretion significantly at 3 and 6 months and at 6 months serum 
iPTH concentration and 24h urinary hydroxyproline excretion had fallen 
significantly in the treated group. During treatment with la-(OH)D3 the serum 
l,25-(0H)2D and 24,25-(01-!),D levels increased significantly. 
In all cases of the la-(OH)D3 group, the second bone biopsy, taken at the end of 
the treatment period, showed a decrease of active resorption and a more positive 
course of trabecular bone volume than the biopsy of the placebo treated counter-
part: trabecular bone volume remained constant or even increased in the 
la-(OH)D3 group. In both groups osteoid seams and osteoblast seams did not 
change significantly. We conclude that treatment with la-(OH)D3 during 6 
months inhibits the increased bone resorption seen in glucocorticoid induced bone 
disease, while bone formation is not suppressed by this therapy. 
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INTRODUCTION 
The pathophysiology of osteoporosis associated with GCexcess is complex. The 
well-known decrease of intestinal absorption of Ca (Gallagher et al., 1973) and 
increase of renal loss of Ca (Wajchenberg et al., 1969) may both stimulate PTH 
secretion. In short-term experiments a direct stimulatory effect of GC on the 
secretion of PTH has also been observed (Fucik et al., 1975; Au, 1976). Thus 
secondary hyperparathyroidism may contribute to the loss of bone in patients 
treated chronically with pharmacological doses of GC. The significance of 
changes in vitamin D status for the pathogenesis of glucocorticoid bone disease 
remains controversial. Both normal and decreased serum levels of 25-(0H)D 
(Klein et al., 1977) and 1,25-(0H)2D (Chesney et al., 1978; O'Regan et al., 1979; 
Seeman et al., 1980) have been reported. Intending to counteract the effects ofGC 
excess on intestinal absorption of Ca, and to inhibit PTH secretion and bone 
resorption, we have conducted a double-blind placebo-controlled trial with 
la-(OH)D3 in patients on chronic GC treatment. We report here the biochemical 
and histological data obtained during this trial. 
PATIENTS AND METHODS 
Fourteen patients treated chronically (range 6-192 months) with a pharma-
cological dose of GC were matched in pairs for sex, age, dose of GC and under-
lying disease (Table 8.1). After obtaining informed consent individuals from each 
pair entered the study within a 3 month period to minimize seasonal bias. No 
medication with known influence on bone metabolism was used. All patients with 
chronic obstructive lung disease used a ,B-adrenergic drug and a xanthine-
derivative. Dietary intake of Ca was at least 500 mg daily. Patients were not 
immobilized. All women were premenopausal. Renal disease was excluded and 
the two patients with liver disease were in a stable phase with normal values for 
serum albumin and coagulation factors. One patient from each pair was treated 
with a daily dose of 2 p.g la-(OH)D3 (Etalpha®, Leo Pharmaceutical Products, 
Holland) for 6 months, while the other patient received a placebo (in double-blind 
fashion). In retrospect the duration of previous GC treatment appeared to be 
somewhat longer in the la-(OH)D3 treated group than in the placebo group (mean 
81 versus 57 months). 
One patient (no 2 of the la-(OH)D3 treated group) had a crush fracture of one 
thoracic vertebra. Rib fractures had occurred in patient no 1 of the placebo group. 
During the period of treatment no additional fractures occurred. In 7 other 
patients radiological density of the spine appeared to be decreased. Four of these 
were in the placebo group. Bone mineral content was measured by photon 
absorptiometry at the distal third of the right radius (Norland-Cameron absorp-
tiometer). This measurement was carried out before treatment and subsequently 
at intervals of3 months. The initial values reported in Table 8.1 were corrected for 
bone width (BMC/BW, g/cm2). In our laboratory mean values (±lSD) for 
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TABLE 8.1 
CLINICAL CHARACTERISTICS AND BONE MASS PARAMETERS AT THE START OF THE TRIAL 
PLACEBO 1a-(OH)D 3 
average daily average daily 
dose of bone trabecular dose of bone 
prednisone mineral bone prednisone mineral 
pair sex age diagnosis during trial content* volume• sex age diagnosis during trial content 
F/M yrs mg g/cm 2 % F/M yrs mg g/cm 2 
F 30 COLD 22 0.67 11. 1 F 21 COLD 16. 5 0.69 
2 M 60 COLD 15 0.69 15.4 M 54 arthritis 15 0.66 
3 F 42 COLD 10 0.68 21.2 F 36 COLD 3 x 0. 5 dexa 0.58 
4 F 24 CALD 13.5 0.46 15.9 F 21 CALD 10 0.61 
5 F 35 SLE 15 0.69 23.6 F 28 SLE 20 0.63 
6 F 37 SLE 9. 5 0.68 20.3 F 27 SLE 10 0.65 
7 F 45 COLD 10 0.68 11. 1 F 51 COLD 10 0.58 
COLD: Chronic Obstructive Lung Disease; CALD: Chronic Active Liver Disease 
* Photonabsorptiometry of the radius. For normal range see Methods 
• Histomorphometry of iliac crest bone. For normal values see Methods 
trabecular 
bone 
volume 
% 
16.6 
15. 3 
17.3 
17. 2 
19.4 
14.5 
22.0 
normal women (age 20-60 years, (n =59) and for normal men (age 20-60 years, n = 
36) are: 0.68 ± 0.06 and 0.77 ± 0.06 g/cm2, respectively. 
Before treatment, after 3 and 6 months of treatment and 3 months after the 
conclusion of the treatment period, serum Ca, P, creatinine, total protein and 
alkaline phosphatase were determined by means of a Technicon-Autoanalyzer in 
a blood sample obtained after an overnight fast. At the same time, iPTH was 
determined by radioimmuoassay (RIA) with a sheep antiserum reacting with the 
mid-region (44-68) of the PTH molecule (kindly assayed by Dr. W.H.L Hackeng, 
Municipal Hospital Bergweg, Rotterdam). Levels of serum vitamin D metabolites 
were determined as previously described (Juttmann et al., 1981"). In Table 8.2 
normal values are given as means over the year (Juttmann et al., 198lb). Intestinal 
absorption of47 Ca was studied by means of an external counting method (Armac, 
right forearm) (Juttmann et al., 1978) together with the 24h urinary excretion of 
Ca. Before and after 6 months of treatment urinary hydroxyproline was deter-
mined in 2-4 successive 24 h collections. A collagen poor diet was used for 3 days 
before and during the collection period. Hydroxyproline was determined after 
resin uptake and hydrolysis (Hypronosticon, Organon Teknika). 
At the beginning and at the end of the treatment period bone biopsies were 
taken from the iliac crest 3 em dorsal to the anterior superior iliac spine on 
contralateral sites successively, using a trephine with an internal diameter of 6 rnm. 
Undecalcified specimens were embedded in methyl metacrylate and cut into 
sections of 5 ,urn. From each biopsy 6 sections were measured at distances of at 
least 100 ,urn. For each section this involved an area of 13.7 mm2 • Staining was 
done with a modified Von Kossa procedure and histomorphometry was perform-
ed by means of x-y tabloid connected to a PDP-II computer using a specially 
developed program (Birkenhager-Frenkel et al., 1980). Parameters for bone 
density (trabecular bone volume as a percentage of the section area measured), 
bone formation (osteoid and osteoblast seams length as percentage of the total 
trabecular perimeter) and bone resorption, (number of osteoclasts per section area 
and active resorption i.e. interface of osteoclasts and mineralized bone surface as a 
percentage of total trabecular perimeter) were measured. For the age groups 
involved the means of the normal trabecular bone volume vary from 21.6 to 23.5% 
(Meunier et al., 1973). The normal values of active resorption have been calculated 
from the data of Bordier & Tun Chot (1972) and Merz & Schenk (1970). For the 
comparison of the changes of parameters as observed in the individuals of 
matched pairs, Wilcoxon's matched-pairs signed-ranks test was used. For correla-
tions Spearman's rank correlation test was applied. 
RESULTS 
Initial investigations 
Biochemistry: The average initial values for most biochemical parameters fell 
within the normal range, one exception being the level of 24,25-(0H)2D (Table 
8.2). Initial serum iPTH level was above the normal range in only I patient of each 
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TABLE 8.2 
BIOCHEMICAL PARAMETERS AT THE START OF THE STUDY, AFTER 3 AND 6 MONTHS TREATMENT WITH 
1a-(OH)D3 (1a) OR PLACEBO (PI) AND 3 MONTHS AFTER DISCONTINUING MEDICATION 
serum 
reference range 
or mean ± 1 SO 
PI 
initial 
mean ± 1 SO 
1a 
3 months 
mean 6 
PI 1a 
6 months 
mean 6 
PI 1a 
3 months off 
treatment 
mean /::, 
PI 1a 
Ca 2. 25 - 2. 75 2. 36 ± 0. 09 
mmol/1 
2.35 ± 0.13 +0.03 +0,06 -0.03 +0.07 -0.02 +0.01 
iPTH 2 - 12 
pmol/1 
7.2 ± 4.4 7.4 ± 4.8 -0.8 -1. 7 +2.6 -3. 1* +3. 0 +4, 1 
25-(0H)D 54. 3 ± 22. 1 
nmol/1 
50.6±24.5 51.1 ± 36.2 +4.3 -6.0 -0.4 -5. 5 +3.8 -11.8 
24, 25-(0H)2 D 
1 ,25-(0H)2 D 
urine 24 h 
Ca 
hydroxyproline• 
4.6 ± 2.2 2.1 ± 1.1 
nmol/1 
160 ± 54 149.0 ± 35.1 
pmof/1 
< 275 
mg 
15 - 43 
mg 
189 ± 81 
30 ± 3 
2.1 ± 1.0 -0.1 +1.1* +0.9 +1.8 +0.4 +0.4 
110.8 ± 34.0 +2.7 +50.2* -19.9 +38.8 -14.0 +7. 1 
1 78 ± 86 +18 +242* +30 +178* +27 -18 
37 ± 13 -6 -18* 
intestinal 47 28.5-55.0 42.9 ± 8.0 48.4 ± 8.2 +3.4 +21.0* +4.0 +22.1* +4,1 +1.0 
absorption of Ca % 
D.: difference between the mean and the mean initial value 
* p<0,05: Wilcoxon's matched-pairs signed-ranks test 
(comparison of 6 values obtained for the individuals of each pair) 
11 6 pairs 
group. Only I patient of the placebo group showed a subnormal fractional 
intestinal absorption of 47Ca and in 3 patients (2 of the placebo group) the 24h 
urinary excretion of Ca exceeded 275 mg. 
Bone histomorphometry: In 7 of the 14 patients the trabecular bone volume(%) was 
low (Table 8.1 and Fig. 8.1). The mean active resorption(%) (Table 8.3) as well as 
the osteoid seams (%)turned out to be high, while osteoblast seams(%) were 
normal. 
Bone mineral content. All the initial values except one were in the normal range 
(Table 8.1). 
TABLE 8.3 
DIFFERENCES IN MORPHOMETRIC RESULTS BETWEEN FIRST AND SECOND 
ILIAC CREST BIOPSIES OF MATCHED PATIENT PAIRS 
PLACEBO 1a-(OH)D3 Wilcoxon's 
matched-pairs 
pre- 6 pre- 6 signed-ranks 
treatment months treatment months test normal 
parameters mean mean mean mean p value values 
trabecular 
bone 16.9 14.5 17.5 19.9 < 0.05 22.0* 
volume {%) 
active 1.10 1. 24 0.92 0.34 < 0, 05 0. 01 - 0.30 111 resorption (%) 
* Meunier et al. ( 1973) 
• Calculated from Bordier & Tun Chat (1972) and Merz & Schenk (1970) 
Double-blind placebo-controlled trial with la-(OH)D3 
Biochemistry: Comparing the paired individuals we found no changes in serum Ca 
(corrected for total protein), P, alkaline phosphatase and 25-(0H)D concentra-
tions during the observation period. Hypercalcaemia did not occur in any of the 
patients treated with la-(OH)D3• 47Ca absorption and 24h urinary excretion ofCa 
appeared to have increased significantly after 3 and 6 months of treatment with 
la-(OH)D3 as compared to the course of the values in the placebo group, while 
iPTH showed a decrease which was significant after 6 months treatment, followed 
by a significant increase 3 months after the conclusion of the trial (as compared to 
the value after 6 months treatment). As expected, the serum level of 1,25-(0H)2D 
rose during treatment with la-(OH)D3 (after 3 months of treatment significantly). 
Simultaneously the concentration of24,25-(0H)2 D had also increased significant-
ly (Table 8.2). After 6 months treatment a significant decrease of 24h urinary 
hydroxyproline excretion was found in the la-(OH)D3 treated patients. Three 
months after terminating the treatment, none of the parameters studied differed 
from the values found at the beginning of the trial in both groups. 
Bone histomorphometry: In Table 8.3 the changes of the values of trabecular bone 
volume(%) and active resorption(%) of the individuals treated with la-(OH)D3 
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Figure 8.1 Initial trabecular bone volume percentage (TBV%) of the patients compared to age related 
normal values after Meunier eta!. (1973). The numbers correspond to the patient pairs as listed in 
Table 8.1. 
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Figure 8.2 Individual and mean± 1 SD values for trabecular bone volume percentage (TBV%) of the 
patients treated with placebo or la-(OH)D3 at the start (to) and 6 months later at the end of the treat-
ment period (t6). The shaded area indicates the normal values (mean± 1 SD) for females in the third 
decade after Meunier eta!. (1973). 
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Figure 8.3 Individual and mean ± 1 SD values for active resorption percentage of trabecular bone 
surface (AR%) in the patients treated with placebo or lo:-(0H)D3 at the start (t0) and the end (t6) of the 
treatment period. The shaded area indicates the normal range as calculated from data ofBordier & Tun 
Chat (1972) and Merz & Schenk (1970). 
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Figure 8.4 Individual and mean± I SD values for the number of osteoclasts per surface unit section 
area of trabecular bone in the patients treated with placebo or lo:-(0H)D3 at the start (to) and the end (t6) of the treatment period. The shaded area indicates the normal range after Bordier & Tun Chot 
(1972). 
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are compared with those of his/her placebo-treated counterpart. Comparing the 
changes of trabecular bone volume observed in each pair of patients, the 
IO!-(OH)D3 treated individuals showed a larger increase or smaller decrease (Fig. 
8.2). During treatment with 1a-(OH)D3 active resorption and the number of 
osteoclasts per section area (Fig. 8.3 and 8.4) decreased in all patients. Whenever a 
decrease was found in a patient of the placebo-group, it was smaller than in the 
matched 1a-(OH)D3 treated patient. Bone formation parameters (osteoid seams 
(%),osteoblast seams(%)) did not change significantly within the pairs of patients. 
Bone mineral content did not change significantly in either group during the treat-
ment period. 
DISCUSSION 
In general the initial concentration in serum of Ca, iPTH and the three vitamin D 
metabolites studied was normal (Table 8.2). The only exception is the subnormal 
average level of24,25-(0H),D. Although it has been suggested that this metabolite 
of vitamin D might be important for the mineralization of bone matrix by a direct 
action on bone (Kanis eta!., 1978), its biological activity or role has not yet been 
established (Papapoulus eta!., 1980). Although increased levels ofiPTH in serum 
in chronic GC excess have been reported (Bressot eta!., 1979; Hahn eta!., 1979b), 
we found a supranormal concentration in only two patients. Mean urinary Ca and 
hydroxyproline excretion were also normaL Initial values of 1,25-(0H),D levels 
were not low, in contrast to what has been reported by some authors (Chesney et 
a!., 1978; O'Regan et a!., 1979) and in agreement with the normal average 
intestinal absorption of47Ca we observed. Initial 47Ca absorption, urinary Ca and 
levels of the three metabolites of vitamin D studied did not correlate with each 
other. However, initial serum iPTH levels were positively correlated with the 
1,25-(0H)2D concentrations (r, = 0.53, p < 0.05). 
During treatment with 1a-(OH)D3, a significant rise of "Ca absorption and 
urinary Ca excretion was seen after 3 and 6 months (Table 8.2). Serum iPTH levels 
were significantly lowered after 6 months. Urinary hydroxyproline (measured in 6 
pairs) after 6 months treatment also fell significantly (Table 8.2). The decrease of 
these two parameters did not correlate. The serum level of 2 of the 3 vitamin D 
metabolites studied, 1,25-(0H)2D and 24,25-(0H),D, were found to have risen 
after 3 months treatment with la-(OH)D3 • The formation of24,25-(0H)2D from 
25-(0H)D in the kidney is known to be stimulated by l,25-(0H)2D (Tanaka & 
DeLuca, 1974). We have as yet no explanation for the fact that after 6 months 
treatment with la-(OH)D3 the levels of these 2 metabolites were no longer 
significantly increased in comparison with the initial values. The significance of 
the correction by 1a-(OH)D3 oft he initially low 24,25-(0H)2D concentrations for 
the changes in bone histology remains to be assessed. Three months after the 
conclusion of the trial serum iPTH, 1,25- and 24,25-(0H)2D, urinary Ca and "Ca 
absorption all had returned to the initial value. 
The fact that no change in the bone mineral content of the radius occurred in 
both groups of patients is not surprising, as at this site it is almost exclusively 
cortical bone which is measured. 
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The initial histomorphometrically determined trabecular bone volume(%) was 
negatively correlated with active resorption (%) (r, = 0.54, P < 0.025). It is 
therefore not surprising that the 6 patients who had a subnormal trabecular bone 
volume, also showed the greatest degree of bone resorption. No relationship was 
found between trabecular bone volume and active resorption on one hand and 
iPTH, 1,25-(0H)2D and 47Ca absorption on the other. 
The raised active bone resorption, that was observed in the majority of our 
patients, might be due to an enhanced sensitivity of the bone to PTH. During 
short-term administration of pharmacological doses of GC, responses of bone 
and kidney cells to PTH have been shown to be increased with regard to the 
production of cAMP and 1 ,25-(0H)2D (Chen & Feldman, 1978; Gennari et al., 
1981; Braun et al., 1982). 
After 6 months of treatment with la-(OH)D3, active bone resorption had 
diminished in all 7 patients and this parameter became normal in 6 of them. The 
same applied to the total number of osteoclasts. Bone resorption and bone 
formation are normally rather tightly coupled processes (Frost, 1963), which 
implies that bone formation is dependent upon immediately preceding bone 
resorption in the same area. It may therefore be of importance that in our patients 
treated for 6 months with rather a high dose of la-(OH)D3 bone resorption was 
not completely inhibited. Trabecular bone volume either had increased or had 
decreased to a lesser extent than in the placebo treated counterparts. It appears 
that the enhanced activity of bone resorbing cells'+' had been counteracted by the 
administration of la-(OH)D3 by inhibition of the PTH secretion, either directly or 
by the stimulation of intestinal Ca absorption. No correlation was found between 
the extent of the decrease of active bone resorption or the increment of trabecular 
bone volume and the decrease of the serum iPTH level, the increase of 
1,25-(0H)2D concentration or the increase of intestinal Ca absorption. On the 
other hand, the degree of inhibition of active bone resorption appeared to be 
reflected in the extent of the fall in urinary hydroxyproline (r, = 0.71, 0.10 > P > 
0.05, n = 6). The somewhat surprising fact that the degree of inhibition of bone 
resorption seems to correlate with the change ofhydroxyproline excretion, but not 
with the decrease of the iPTH level may be due to a lack of sensitivity of the 
radio-immunological technique or to the involvement of other bone resorption-
determining factors. 
Hahn et al. (1979b), who treated patients with GC osteoporosis with 25-hydro-
xyvitamin D, similarly found a rise of 47Ca absorption and of urinary Ca and 
suppression of iPTH values. The only change in bone histomorphometry they 
found after 12 months (comparing seven 25-(0H)D3-treated patients with seven 
unmatched control patients) was a decreased number of osteoclasts in the cortical 
part of the biopsies. The more positive result we found, after 6 months treatment 
with la-(OH)D3, must be due partly to the different design of our study, allowing 
us to apply Wilcoxon's matched-pairs signed-ranks test in which even a less 
negative course of a parameter within a pair contributes to a significant result of 
(+J It might be better to use here the term enhanced recruitment of bone resorbing cells. 
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the test. s,nensen et al., ( 1977) administered 2p.g of la-(OH)D3 for 3-4 months to 
3 patients with prednisone induced bone loss and 7 patients with senile osteo-
porosis: fractional 47Ca absorption and urinary Ca rose, while the authors claimed 
that histomorphometry in both types of patients showed changes comparable to 
those reported here. Several authors (Marshall & Nordin, 1977; Gallagher et al., 
1979) have found that the low intestinal absorption of Ca in postmenopausal 
women is caused by a low production of l,25-(0H)2D3• Evidently, the condition 
can be corrected by administration of 1,25-(0H)2D3, leading to a more positive 
balance ofCa skeletal mass. One should not, however, see too much of an analogy 
between GC induced bone loss and postmenopausal osteoporosis. In GC excess 
the negative skeletal balance is probably caused by two mechanisms. Apart from 
an increased resorption of bone that can be counteracted by raising 1,25-(0H)2D 
levels and intestinal Ca absorption, excess of GC also causes inhibition of protein 
synthesis by the bone forming cells (Raisz, 1980). It is not clear yet, whether 
administration of la-(OH)D3 can counteract this inhibition to any degree. From 
the work reported here we conclude that there is a need for a similar study over a 
longer period, using a lower dosage of la-(OH)D3 in which a parameter of bone 
formation rate is measured. 
For references see the common reference list. 
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CHAPTER IX 
(Addendum to Chapter VIII) 
Comparison of intestinal radiocaldum absorption and 
intestinal calcium balance in patients treated with 
glucocorticoids with and without la-(OH)D3. 
INTRODUCTION 
Complementary to the study of fractional intestinal 47Ca absorption in GC treated 
patients, this Chapter contains Ca balance data obtained in 5 of the 7 patients 
pairs from the study, described in Chapter VIII. Initial data and data obtained 
after 6 months treatment with placebo or la-(OH)D3 have been compared. 
METHODS 
During theCa balance studies the patients were admitted to the metabolic ward. 
Each balance study started with an equilibrium period of 3 days, followed by 2 
collection periods of 6 days. Using the diet history of the patient (calories, Ca and 
P), the balance diet was prepared from stock for the whole study and the meals 
were stored frozeri until use. The diet was analyzed for Ca in duplicate. Poly-
ethyleneglycol (PEG,MW 4000) was administered in a dosage of 400 mg 3 times 
daily as nonabsorbable marker to correct faecal collection. The start and end of a 
collection period were marked by faecal appearence of orally administered 
carmine-red. In the diet (l day collection) and faeces (6 day collection period) Ca 
content was determined after dilution with distilled deionized water, homogeniza-
tion and destruction with HN03 (65% v/v) and HCl04 (70% v/v) by means of 
EGTA titration of a fluorescent Ca-calce.ine complex (a modification of the 
method described by Wallach & Steck (1963)). The faecal PEG concentration was 
determined by a turbidimetric method (Boulter & McMichael, 1970). The faecal 
recovery of PEG was always between 80 and 90%. Net intestinal Ca absorption 
was obtained by substracting daily faecal loss ofCa f:om daily oral Ca intake. Net 
intestinal Ca absorption is composed of true intestinal absorption minus endoge-
nous Ca excretion. From Wilkinson's study (1976) of the metabolic Ca balances in 
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more than 200 individuals, we derived a mean± 2 SD value for the fractional net 
Ca absorption of28 (± 12)% (at an average daily Ca intake of 1100 mg). 
The fractional intestinal 47Ca absorption, determined by an external counting 
method as described by Juttmann et al. (1978), was always performed at the end 
of the balance study, while the patient used his normal diet. Our normal range is 
28,5-55,0% (n=l9). 
For statistical analysis Student's t-test and Spearman's correlation test were 
employed. 
RESULTS 
Both dietary fractional Ca absorption and fractional 47Ca absorption were mea-
sured in 5 of the 7 patient pairs described in Chapter VIII (no. 1, 3, 4, 5 and 7), at 
the start of the study (t0 ) and after 6 months (t6). At t0 the fractional intestinal 
absorption measured by radiocalcium was below the normal range in only one 
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Figure 9.1 Individual and mean values± 2 SD for fractional intestinal absorption of 47Ca and net 
intestinal 4°Ca absorption in patients on chronic GC at the start of the study (t0) and after treatment 
with pl~cebo or lo:-(OH)D 3 for 6 months (t6). The shaded areas indicate the normal range of 47Ca 
absorptiOn (Juttmann et al., 1978) and the mean value± 2 SD of net 4°Ca absorption (Wilkinson, 
1976). The numbers correspond to the patient pairs described in Chapter VIII. 
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patient (patient number 3 from the placebo-group). However, the net Ca absorp-
tion derived from the balance was lower than -2 SO of the mean value from 
Wilkinson et al. in 6 of the 10 patients at the start of the study (Fig. 9.l).ln patient 
number 5 from the placebo- and patient number 7 from the !a-group a net 
intestinal Ca secretion was found. In all 5 patients in the lo:-group a significant 
increase of the intestinal Ca absorption was observed with both methods, after 
treatment with la-(OH)D3 (2 J.l.g daily for 6 months). There was no correlation 
between the results of both measurements in these 5 patient pairs at t 0 and t6 
(Spearman's correlation test). 
DISCUSSION 
Reeve et al. (1980b) compared fractional net intestinal Ca absorption, calculated 
from balances, with radiocalcium absorption studies and found a rather wr:ak 
correlation with maximum and mean rate of absorption of the tracer. Comparing 
the two methods for the determination of intestinal Ca absorption, one has to 
realize that the processes measured are not identical. 
Radiocalcium absorption is studied by us with 200 mg of Ca as carrier in an 
easily absorbable, largely ionized form in an individual after an overnight fast. 
These circumstances enhance Ca absorption. In the radiocalcium absorption test 
one measures 47Ca uptake into a large body pool of 4°Ca over 5 hours. Assuming 
that within this period no substantial amount of47Ca is secreted into the intestinal 
lumen, one measures only unidirectional Ca flux from lumen to tissue, mainly in 
the proximal part of the small intestine. When fractional Ca absorption is calculat-
ed from the difference between dietary intake and faecal excretion, one obtains 
the net result of Ca-efflux and Ca-influx (from and to the intestinal lumen) along 
the entire length of the gastrointestinal tract. The fact, that in normal people a 
higher mean value ( 40%) has been found for unidirectional Ca-efflux (expressed as 
fraction radiocalcium absorbed) than for fractional net Ca absorption calculated 
from theCa balance (30%), is probably the result ofCa secretion (Ca-influx). The 
10% difference between the results of these two methods agrees quite well with the 
reported endogenous Ca secretion of 100-200 mg per day at an intake of 1000 mg 
Ca (Nordin et al., 1976). 
The discrepancy between the values obtained by the two methods is accentuated 
in patients treated with a moderately high dose of GC. This is in agreement with an 
enhancement of intestinal Ca secretion by excess GC as reported for dogs (Collins 
et al., 1962), rats (Ferretti et al., 1978) and by us in rat small intestinal loops 
(Chapter Vll). 
During treatment of patients on GC with la-(OH)D3 the intestinal Ca absorp-
tion increased mainly by stimulation of the unidirectional Ca-efflux, represented 
by 47 Ca fractional absorption, to supranormallevels. As a result the net intestinal 
absorption of Ca was normalized. 
Studies in man on the intestinal secretion of parenterally administered radio-
calcium during GC excess have to be done to confirm this hypothesis. 
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CONCLUSIONS 
The intestinal fractional absorption of47 Ca, as measured over 5 hours after an oral 
load by an external counting method, is normal in patients treated chronically 
with a moderately high dose of GC (cf. Lekkerkerker et al., 1970; Klein et al., 
!977). Net Ca absorption expressed as fraction of dietary Ca, however, is sub-
normal in a considerable number of these patients, probably as a result of an 
increased endogenous Ca secretion. Treatment with la-(OH)D3 can reverse this 
low net Ca absorption by increasing the true Ca absorption (via stimulation of the 
unidirectional Ca-efflux) to supranormallevels. 
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CHAPTER X 
General discussion 
In this Chapter we will try to fit the results of the clinical trial and the other 
· experimental investigations into a concept of the pathogenesis of GC induced 
bone disease. 
An increased sensitivity of the renalla-hydroxylase to the stimulatory action of 
PTH might be responsible for the rise of serum 1,25-(0H),D during short-term 
GC administration in men (Chapter V). Teleologically, this rise is a beneficial 
reaction that, by stimulation of the intestinal absorption of Ca and P, could 
compensate for the primary induction of intestinal and renal loss of both minerals 
induced by high dose GC. The rapidity of the rise of the serum 1,25-(0H),D level 
during infusion with hydrocortisone (see Chapter V) makes it improbable that it is 
the result of the inhibition of intestinal Ca absorption, leading in turn to stimula-
tion of 101-hydroxylase by a decrease of serum ionized Ca.lt is well-known that the 
negative influence of excess GC on intestinal Ca absorption and the stimulatory 
effect on renal Ca secretion become apparent after days. In the hypoparathyroid 
patients we found an increase of urinary P and in normal individuals a decrease of 
serum P during hydrocortisone infusion within hours. The possibility that this 
stimulates !a-hydroxylase is not excluded. However experimentally, serum P 
levels have to be very low to demonstrate the enhancing effect on !a-hydroxylase 
activity (Tanaka & DeLuca 1973). Furthermore, in our study of the normal and 
hypoparathyroid individuals, using a prednisone dosage that admittedly was 
much lower than that of the experiments with hydrocortisone, we saw no change 
of the serum P level during the first 5 days. 
The high level of 1,25-(0H),D is not sustained, however, when the administra-
tion of prednisone is continued in normal individuals for more than 5 days, in 
contrast to patients with PHP. Possible explanations for the transient character of 
this response are given in Chapter V. The diminished intestinal Ca absorption and 
the activation of vitamin D by GC excess are probably different, not causally 
related responses. 
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The loss of Ca, caused by decreased intestinal absorption and increased renal 
clearance, leads to secondary hyperparathyroidism and this is reflected by an 
increased number of osteoclasts on histological examination of trabecular bone. 
However, in our patients chronically treated with GC serum PTH levels have 
predominantly been found in the normal range. The combination of the character-
istics of bone histology and the generally normal PTH concentrations point to an 
increased sensitivity of the bone to the resorbing action of PTH caused by the GC 
excess. An alternative explanation would be the involvement of an unknown 
bone-resorbing agent. In vitro the release of bone mineral is diminished after 
treatment with high doses ofGC, indicating that osteoclasis are depressed in their 
activity. Probably an increased recruitment of osteoclasis in combination with a 
decrease in bone (matrix) formation results in a net loss of bone. The amount of 
bone formed and resorbed per unit time at the level of the BMU's is schematically 
illustrated for the normal situation and during GC excess in Fig. 10.1 A and I 0.1 8 • 
Enhancement or permissive effects of GC on the action of other hormones (e.g. 
glucagon and epinephrine) have frequently been reported in the literature (for 
review see Baxter & Forsham, 1972; Granner, 1979). At the cellular level this type 
of effect could be obtained through the influence of GC on second messengers as 
cAMP and cGMP <+>.The amplification of hormonal effects by GC probably lies 
beyond the generation of cAMP (Lamberts et al., 1975; Granner, 1979), but data 
are not conclusive. The activity of cAMP-phosphodiesterase is reported to be 
inhibited by GC in several tissues (Manganiello & Vaughan, 1972; Schmidtke et 
al., 1976). The "Ca-generating system" is another pathway through which hormo-
nes can transduce their effect on target cells. GC can induce, probably via gene 
activation, the synthesis of an antiphospholipase A2 protein (macrocortin or 
lipomodulin), as recently described in guinea pig lung tissue and rat peritoneal 
leucocytes (Flower & Blackwell, 1979; Blackwell et al., 1980). Changes in compo-
sition and conformation of cellular membranes, altered turnover of phospholi-
pids, decreased release and production of arachidonic acid and prostaglandins 
could result. Via such mechanisms not only the availability of membrane 
hormone-receptors can change, but above all cellular Ca-influx can be limited by a 
decreased production of substances with a "Ca-gating" action (arachidonic acid, 
certain prostaglandins). In theory, GC can modulate the effects of other hormones 
via such changes of intracellular Ca as second messenger. 
The decreased influx of Ca in BBMV prepared from small intestine of rats pre-
treated with triamcinolone is probably an example of decreased "Ca-gating" in 
the cell membrane (Chapter VI). The active vitamin D metabolite I ,25-(0H),D3 
was capable to antagonize this GC effect. Active vitamin D metabolites are 
thought to enhance Ca entry across the intestinal brush border membrane by 
changes in the phospholipid metabolism (Matsumoto et al., 1981) resulting in 
an increased phosphatidylcholine/phosphatidylaethanolamine ratio. One might 
speculate whether a similar interaction between GC and 1,25-(0H)2D applies to 
other target tissues of both hormones, such as bone and kidney cells. A decreased 
i+J cyclic guanosine 31 ,5 1-monophosphate 
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Figure 10.1 In this figure the activation frequency (!J.) of basic multicel!ular units (BMU) per unit time 
is illustrated schematically. The amount of bone resorbed (R) or formed (F) within a given time period 
is presented by means of"stair-cases". The height of each step represents the amount of bone resorbed 
or formed by one BMU during the whole period of its existence. Net gain or loss of trabecular bone 
volume (TBV) is obtained by the difference between Rand F. 
A. In the normal situation Rand Fare in equilibrium orR exceeds F slightly. 
B. We postulate that duringhypercortisolism an increased recruitment ofBMU's (~J.!) is accompanied 
by a decreased bone forming and bone resorbing activity per BMU. 
C. When 10'-hydroxylated derivatives of vitamin Dare given to patients chronically treated with GC, 
the activation frequency of bone resorbing units is depressed to subnormal (p\) The amount of 
bone resorbed per BMU may be increased. Bone formation is determined by a progressively 
decreasing activation frequency of bone forming units (resulting from persistent coupling of bone 
formation and resorption) and a gradually increasing amount of bone formed per newly activated 
BMU when la:-(OH)D3, directly or indirectly, has !growth factor-like! activity. 
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availability of intracellular Ca, induced by GC excess in renal tubular cells and 
precursors of bone cells, could act as extra stimulus for the renalla-hydroxylase 
enzyme and the recruitment of(pre)osteoclasts by PTH. However, one should be 
careful not to see too much of an analogy between BBMV from rat small intestinal 
villous cells, specialized in Ca transport and membranes of other cells. Further-
more, when Ca-influx is inhibited, one would generally expect a diminished 
biological response to hormones for which Ca probably also acts as a second 
messenger. 
The beneficial effect of treatment with ICY-(0H)D3 on the progression of GC 
induced bone disease is demonstrated by the results of the clinical trial, described 
in Chapter VIII. There are several loci where active vitamin D metabolites 
interfere in the pathogenesis of GC osteoporosis. This is schematically illustrated 
in Fig. 10.2 and concerns the following main points: 
I. Fractional intestinal absorption of 47Ca and circulating levels of 1,25-(0H),D 
generally were within the normal range in the patients chronically treated with 
GC. For the net intestinal 40Ca absorption we found values below the normal 
range in a large number of these patients (Chapter IX). Extrapolation of the data 
on the influence of high doses of GC on Ca fluxes in the experiments with rat 
ligated small intestinal loops in situ suggests, that GC have an important effect on 
intestinal Ca absorption by increasing the Ca secretory flux. Treatment with 
1CY-(0H)D3 (being very rapidly converted to 1,25-(0H)20 3) will compensate for 
this intestinal Ca loss by stimulating the unidirectional intestinal Ca absorption in 
the proximal part of the small intestine to a supranormallevel. A hypothesis on the 
effects of GC and/ or I ,25-(0H),D3 on cellular and paracellular fluxes of Cain the 
rat small intestine, derived from our data on in situ experiments with loops 
(Chapter Vll) and studies with BBMV (Chapter VI), is schematically illustrated in 
Fig. 10.3. 
II. Active vitamin D derivatives inhibit the increased secretion ofPTH and/or 
the enhanced recruitment of pre(osteoclasts) by the stimulation of intestinal Ca 
absorption and possibly also directly. In the histomorphometric study of bone 
from our patients treated for 6 months with !CY-(0H)D7, this was reflected by the 
striking decrease ofthe parameters for bone resorption. In the la:-(OH)D3 treated 
patients the positive course of trabecular bone volume, as compared to the 
placebo treated ones and the lack of change of the parameters for bone formation, 
are evidence at least for an unhampered bone formation. 
Ill. A stimulatory effect of the treatment with !CY-(0H)D3 on bone formation 
cannot be excluded. Factors reported to have a beneficial effect on bone formation 
and/or mineralization areCa and P (Bingham et al., !974; Harris et al., 1976), 
1,25-(0H)2D (Larsson et al., 1977) and 24,25-(0H)2D (Kanis et al., 1978). We 
found low serum levels of24,25-(0H),D in about half of the patients treated with 
medium dose of GC, which levels rose during the administration of la-(OH)D7• 
The increment of intestinal Ca absorption in the patients treated with 
la-(OH)D3 was largely excreted in the urine. In some patients this led to an 
unacceptable rise in urinary Ca excretion. The data on theCa balances, expressed 
as percentage of dietary Ca intake, in 5 patient pairs before and after 6 months 
treatment with la-(OH)D3 or placebo, are presented in Fig. 10.4. After 6 months 
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Figure 10.2 Main features in the pathogenesis of glucocorticoid itiduced bone disease and the 
influence of treatment with l&-(0H)D3 on its progress in a model derived from the results of our 
studies. 
I An increased intestinal Ca secretion, induced by GC excess, is counteracted by Ja-(OH)D3 via 
stimulation of the intestinal Ca-efflux (lumen to tissue). 
II An increased bone resorption, resulting from an increased PTH secretion or sensitivity to PTH, is 
suppressed by the active vitamin D derivative. 
III Bone formation is unhampered, may be even stimulated, during treatment (6 months) \Vith 
la-(OH)D3. 
treatment with the vitamin D derivative theCa balance showed a tendency to be 
less negative than in the untreated state and was also less negative than in the 
placebo-group, although not significantly, due to rather large inter- and intra-
individual variations. This finding in combination with the positive course of 
trabecular bone mass and the decreased number of osteoclasts as found on bone 
histomorphometry, is strong evidence against a bone mobilizing action of the 
1,25-(0H)2D3, formed from la-(OH)D3, in the dosage used. This is in contrast to 
the negative Ca balances induced by the administration of 1,25-(0H)2D3 (3 p.g 
daily) to normal volunteers (Maierhofer et al., 1983). In that study biochemical 
evidence of increased bone resorption was demonstrable in association \vith 
supraphysiologic serum levels of 1,25-(0H)2D. This may reflect an important 
difference in reactivity of normal bone and bone ofhypercortisolistic patients. 
75 
Normal A 
~-efflux 
BLM~T.T--~, r~--, 
' p 
c 
Ca-gate 
G lucocorticoids 
c 
p 
Glucocorticoids 
+1, 25-(0H) p 3 l, 
' 
' 
' 
' 
' 
' 
' I 
p 
Na, K-
ATPase 
B 
Na, K-
ATPase t 
c 
Na, K-
ATPase t 
Net-flux t 
PD 
Net-flux t 
PDt 
Net-flux+ 
Figure 10.3 Schematic illustration of a hypothetical model for transepithelial Ca fluxes in the small 
intestine. Ca-efflux is composed of cellular (c) and paracellular(p) components. Ca-influx is exclusively 
paracellular (p). During hypercortisolism Ca-efflux is probably increased by "solvem drag" via the 
parace!lular pathway, while the number of "Ca-gates" in the brush border membrane (BBM) is 
diminished. The Ca-influx, however, is stimulated to a larger extent, driven by the more negative 
(lumen to serosa) trammural potential difference (PO) resulting from a stimulated Na,K-ATPase at 
the basolateral membrane (BLM). Treatment with the active vitamin D metabolite 1.25-(0HhD3• 
during GC excess, restores the number of"Ca-gates" in the BBM and the still augmented Ca-influx is 
overruled by stimulation of the transcellular Ca-efflux. 
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placebo 
Total Ca-balance 
%oral intake 
n=5 mean ± 1 SO T 
1a ~(OH)D3 
n=s mean ± 1 SD 
to t6 -~40- to t6 
-~20-
-40-
faecal faecal 
90 ± 1 3 % 87 ± 8 89 ± 12 % 63 ± 
urinary -6o- urinary 
1 9 ± 8 % 22 ± 11 24 ± 10 % 42 ± 
-so-
-100- L_ __ _j 
Ca-balance 
mg ± SD.day~ 1 
1 1 
11 
~71±167 ~73 ± 147 
-84 ± 99 ~46 ± 38 
Figure 10.4 Components ofCa balance presented as percentage of food intake in 5 patients pairs who 
were chronically treated with GC, before (t6) and after 6 months (t6) administration of la-(OH)D3 (2 J.tg daily) or placebo. For methods see Chapter IX. TheCa intake is plotted downwards from the 
base line as 100 percent. Faecal and urinary Ca are represented by open or hatched bars, respectively. 
At the bottom mean values± I SD for theCa balance are given in mg/day. 
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Whether the beneficial effect of la-(OH)D3 in GC induced bone disease is the 
result of suppression of secondary hyperparathyroidism only, or is (also) achieved 
by stimulation of bone formation, is yet to be established. 
To assess the exact value of la-hydroxylated vitamin D derivatives for the 
prevention or treatment of GC induced bone disease, in our opinion, a second 
study with these compounds has to be performed, using a lower dosage for a 
longer observation period and in a larger group of patients with the use of 
non-invasive bone mass measurements (dual photonabsorptiornetry and/or 
computed tomography). One argument to carry out such a study is the possibility 
that the beneficial effect on bone mass observed after 6 months treatment, would 
subsequently be arrested. Bone formation being then depressed to a similar degree 
as bone resorption has been previously. This would be the result of persistence of 
the well-known tight coupling of bone formation to bone resorption. Seen in this 
light intermittent treatment with active vitamin D metabolites would be an 
attractive alternative, as has been reported by Rasmussen et al. (1980), treating 
postmenopausal patients with calcitonin. When, however, one or mo"re vitamin D 
metabolites, c.q. 1,25-(0H),D3 or 24,25-(0H),D3, also act(s) as bone "growth 
factor(s)", the balance between bone formation and bone resorption will remain 
positive beyond 6 months treatment. At the level of the BMU's this may be 
visualized as in Fig. lO.lc. 
With regard to the treatment of postmenopausal and other age related forms of 
osteoporosis with la-hydroxylated vitamin D derivatives, both positive (Gal-
lagher et al., 1982) and negative (Christiansen et al., 1981; Finn et al., 1982) results 
have been reported. The negative results have been obtained with the rather low 
dosage of0,25-0,50 l'g 1,25-(0H),D3 daily. One should realize however, that the 
pathogenesis of GC induced osteoporosis, albeit complex, probably is more 
uniform than that of age related osteoporosis and that increased intestinal loss of 
Ca is an important factor in the negative bone and Ca balances of GC induced 
bone disease. 
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SUMMARY 
Chronic exposure to supra physiologic levels of glucocorticoids is associated 
with the loss of mainly trabecular bone. The result is osteopenia, defined as a 
subnormal bone mass for age, sex, race and body size, while bone mineraliza-
tion is normal. The clinical term osteoporosis is generally used when pathologic 
fractures, especially compression fractures of the vertebrae, occur due to insuf-
ficient supportive strength. In this sense osteoporosis is a frequent complication 
in patients with endogenous or exogenous hypercortisolism. However, one has 
to take into account that the underlying disease for which glucocorticoids are 
prescribed may in itself also cause abnormal bone loss (Chapters I and II). 
An important problem in the diagnosis of osteopenia is that, with the availa-
ble non-invasive radiological and isotope techniques, one only obtains quanti-
tative or semiquantitative information about the local bone mass, usually in a 
periphe,-al (appendicular) part of the skeleton with a preponderance of cortical 
bone. Histomorphometrical measurements in biopsy material from the iliac 
crest provide information on the amount oftrabecular bone at that site and also 
quantitative data on bone resorption and bone formation, reflecting the dyna-
mic process of bone remodeling (Chapter II). 
By their influence on bone turnover, regulators of Ca homeostasis may play 
an important role in the pathogenesis of several forms of osteoporosis. In this 
context the most important regulators of Ca metabolism are parathyroid hor-
mone, calcitonin and vitamin D, which are discussed in Chapter III. The most 
frequent form of osteoporosis (primary) is probably multifactorial in its patho-
genesis and one should realize that changes reported in circulating concentra-
tions of parathyroid hormone and other factors involved inCa homeostasis and 
bone cell activity may not be related to the cause of the process. The regulation 
of vitamin D metabolism and the mode of action of the most active metabolite 
l ,25-dihydroxyvitamin D (l ,25-(0H),D) on its target organs are discussed in 
Chapter Ill. Clinically, the serum level ofCa, P and parathyroid hormone are 
the main regulators of the formation of 1,25-(0H)2D in the kidney. The action 
of 1.25-(0H),D is to stimulate the flux ofCa (and P) into the extracellular fluid 
from intestine, bone and kidney. 
The mode of action of l ,25-(0H)2D has the characteristics of that of a steroid 
hormone: cytoplasm a tic and nuclear receptors have been demonstated and de 
novo protein synthesis is induced by gene activation. 
In Chapter IV a review is given of the literature on the effect of glucocor-
ticollds, at physiological and supraphysiological levels, on regulators of Ca 
homeostasis and bone cell activity. A negative Ca and P balance, resulting from 
a decreased intestinal Ca and P absorption and an increased renal clearance of 
both minerals, appears to be of crucial importance. In this respect the (slightly) 
elevated levels of circulating parathyroid hormone, as frequently reported in 
patients with hypercortisolism, represent probably a state of secondary hyper-
parathyroidism. It is also possible that the secretion of parathyroid hormone is 
directly stimulated by giucocorticoids. Histomorphometric analysis of bone 
biopsy material from patients with hypercortisolism often reveals features of 
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increased bone resorption together with decreased bone formation. The increas-
ed number and/or activity of osteoclasts is not always associated with supra-
normal serum levels of parathyroid hormone. This could be explained by an 
augmented response of (pre)osteoclasts to parathyroid hormone induced by 
glucocorticoids. Glucocorticoids interfere with bone formation by direct inhibi-
tion of the synthesis of bone matrix by osteoblasts and by inhibition of the 
production of local growth factors or of hormones indirectly involved in the 
process of bone formation. 
Glucocorticoid excess affects the target organs of vitamin D (bone, gut, 
kidney). The possible influence of glucocorticoids on the metabolism (activa-
tion) of vitamin 0 itself has therefore been studied rather extensively. Definite 
conclusions, however, cannot be drawn from the data derived from these 
studies. 
In Chapter V we describe the effect of short-term hypercortisolism on the 
metabolism of vitamin D in man, as studied by us, at different levels of 
parathyroid gland activity. During the administration of 30 mg of prednisone 
daily we found within 1-3 days a rise of the concentration of serum l ,25-(0H)2D 
in 6 normal individuals and 8 patients with primary hyperparathyroidism. This 
rise turned out to be dependent on the presence of parathyroid gland activity, as 
in 5 patients with hypoparathyroidism no rise of serum I ,25-(0H),D could be 
detected when the same dose of prednisone was administered for 3-4 days. In 
normal individuals the intravenous infusion of hydrocortisone induced within 8 
hours a similar increase of the serum I ,25-(0H)2D level. An increased sensitivity 
of the renalla-hydroxylase for parathyroid hormone could explain the observ-
ed reaction. No changes in the concentrations of parathyroid hormone, Ca and 
P in the serum were found, capable of stimulating the production of l ,25-
(0H)2D. Furthermore the increase of serum l,25-(0H)2D after injection of 
parathyroid extract in a patient with hypoparathyroidism was distincly enhanc-
ed, when the extract was administered in combination with hydrocortisone. In 
normal individuals the rise of serum 1,25-(0H)2D during prednisone admini-
stration was transient, the concentration of 1,25-(0H)2D returning to basal 
levels after 9 days of prednisone administration. From these data it seems highly 
unlikely that in man changes in the metabolism of vitamin Dare responsible for 
the decrease of the intestinal absorption of Ca, observed during administration 
of similar doses of glucocorticoids for 1-2 weeks. It is, on the other hand, also 
unlikely that the early and transient rise of serum 1,25-(0H)2 D is a reaction to 
the inhibition of intestinal Ca absorption by glucocorticoids. 
We studied the mechanism by which glucocorticoid excess lowers intestinal 
Ca absorption, at subcellular level, using brush border membrane vesicles 
prepared from epithelial cells from the proximal half of rat small intestine 
(Chapter VI). Five days after the injection of a long-acting suspension of 
triamcinolone we found a decrease of the initial rate ofCa uptake in the vesicles, 
presumably resulting from a decrease of the number or activity ofCa carriers in 
the brush border membrane. This decrease of the initial Ca uptake, that proba-
bly is associated with a fall in the transcellular Ca transport, could be antagoni-
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zed by the administration of I ,25-(0H),D1. 
Although the fall in theCa uptake at the level of the brush border membrane 
induced by glucocorticoid excess, is in agreement with the effect reported by 
others in experiments with intestinal segments in vitro, it is probably not the 
transcellular Ca flux that determines the lowered net Ca absorption under these 
conditions. We studied Ca absorption in isolated rat small intestinal loops in 
situ after treatment with triamcinolone. Treatment with triamcinolone increas-
ed the unidirectional Ca-efflux (from lumen to tissue) in the proximal part of 
the small intestine and this flux correlated positively with the net absorption of 
solvent. However, Ca-influx (secretion) into the small intestinal lumen was 
stimulated to an even greater extent, resulting in a decreased net Ca absorption 
along the whole length of the small intestine (Chapter VII). 
The fraction of Ca absorbed from the diet turned out to be subnormal in 6 of 
10 patients on long-term treatment with a medium dose of glucocorticoids 
(Chapter IX).ln only one of these 6 patients the fraction of orally administered 
47Ca (with 200 mg 40Ca as carrier) absorbed in 5 hours was also subnormal. 
Assuming that the fractional intestinal absorption of radioactive calcium is 
representative for unidirectional Ca-efflux, the discrepancy between the two 
methods can be explained by glucocorticoids stimulating the endogenous secre-
tion of Ca. This is in agreement with the results of our in situ experiments with 
rat small intestinal segments (Chapter VII). After treatment with Ia-(OH)D3 
(21'g daily) for 6 months the fraction ofCa absorbed from the diet was normal-
ized in patients on glucocorticoids, while the fractional absorption of 47Ca was 
increased to a supranormallevel. 
The effect of treatment with la-(OH)D3 (2 l'g daily) on the bone disease, 
induced by long-term glucocorticoid treatment, was studied in a double-blind 
placebo-controlled trial of6-9 months with 7 patient pairs matched for sex, age, 
underlying disease and dose of glucocorticoids (Chapter VIII). In general the 
biochemical parameters for Ca- and bone-metabolism (serum Ca, P, alkaline 
phosphatase, parathyroid hormone, vitamin D metabolites and urinary excre-
tion of Ca and hydroxyproline) were all in the normal range at the beginning of 
the study. One exception was formed by the low levels of 24,25-dihydroxy-
vitamin D (24,25-(0H)2D) in the serum present in more than 50 percent of the 
participants. Although serum parathyroid hormone was found to be elevated at 
the start of the study in only one patient, histomorphometry of trabecular bone 
from the iliac crest revealed an increased number of osteoclasts in nearly every 
patient, often in combination with a subnormal trabecular bone volume. 
During treatment with la-(OH)D3 the fractional intestinal absorption of47Ca 
and urinary Ca excretion increased significantly in comparison to the placebo 
treated control patient. After 6 months treatment with la-(OH)D3 the concen-
trations of serum parathyroid hormone and the urinary excretion of hydroxy-
proline had fallen, while in the treated group the concentrations of both I ,25-
(0H),D and 24,25-(0H),D in the serum had risen. Histomorphometric 
comparison of trabecular bone from a second iliac crest biopsy, taken after 6 
months treatment with la-(OH)D3 or placebo, with material from the first 
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biopsy, showed a decrease of bone resorption parameters in all patients treated 
with l"-(OH)D3, while the course of trabecular bone volume was always more 
positive in the patients treated with la-(OH)D3 than in the placebo-treated 
controls. Changes in the parameters for bone formation (osteoblast seams, 
osteoid seams) occurring during treatment, did not differ significantly between 
the treatment groups (Wilcoxon's matched-pairs signed-ranks test). 
On the basis of the results of the studies described in this thesis a concept of 
the pathogenesis of glucocorticoid induced bone disease and of the possibilities 
for its treatment or prevention with active vitamin D derivates is outlined in 
Chapter X. An enhancement of the sensitivity of the renal tubular cells and of 
(pre)osteoclasts for the action of parathyroid hormone by glucocorticoid excess 
is postulated. An antagonism between glucocorticoids and vitamin D expresses 
itself not only at the level of Ca uptake in brush border membrane vesicles, but 
also in an improvement of the intestinal Ca absorption and in a beneficial effect 
on trabecular bone mass when patients, who chronically use glucocorticollds, 
are treated with a la-hydroxylated derivative of vitamin D. It is not known 
whether the improvement in trabecular bone mass results from the suppression 
of parathyroid hormone secretion or is (also) due to a growth factor-like activity 
of the active vitamin D metabolite. 
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SAMENVATT!NG 
Langdurige blootstelling aan suprafysiologische doses glucocorticoiden gaat 
gepaard met een snel verlies van vooral trabeculair bot. Het resultaat is osteo-
penie: een verminderde botmassa voor leeftijd, geslacht, ras en lichaamsbouw, 
terwijl de mineralizatie van het bot nagenoeg normaal is. Wanneer hierbij als 
gevolg van onvoldoende steunfunctie van het skelet pathologische fracturen, 
met name van de wervellichamen optreden, spreken we van osteoporose. 
Osteoporose is dan ook een frequent voorkomende complicatie bij het syn-
droom van Cushing en bij het gebruik van hoge doses glucocorticoiden als 
therapeuticum. Ook de ziekten waarvoor glucocorticoiden worden voorge-
schreven kunnen zelf aanleiding zijn tot een abnormaal snel verlies van bot-
massa. Bij de bestudering van bet effect van glucocorticoiden op bet bot van 
deze patienten dient biermee rekening te worden gehouden (Hoofdstukken I en 
!1). 
Een belangrijk probleem bij bet vaststellen van osteopenie is bet feit dat men 
met de thans gangbare, niet-invasieve radiologische en isotoop-tecbnieken 
kwantitatieve of semikwantitatieve gegevens krijgt van de lokale botmassa, als 
regel in een perifeer deel van het skelet waar corticaal bot overheerst. Histornor-
fometrie van botbiopsiemateriaal b. v. uit de cristailiaca biedt naast de inforrna-
tie over de hoeveelheid (trabeculair) bot ter plaatse ook kwantitatieve gegevens 
over de botafbraak en de daaraan gekoppelde botaanmaak als een momentop-
name in het dynamische proces van botombouw (Hoofdstuk !!). 
Regulatoren van de Ca homeostase kunnen door hun invloed op botafbraak 
en botaanmaak een belangrijke rol spelen in de pathogenese van de diverse 
vormen van osteoporose. De belangrijkste hormonale regulatoren van de Ca 
huishouding: parathyroidhormoon, calcitonine en vitamine Den hun mogelijke 
betekenis voor de pathogenese van osteoporose worden behandeld in Hoofd-
stuk III. Primaire osteoporose is een multifactorieel bepaalde toestand, waarbij 
veranderingen in spiegels van bijschildklierhormoon of andere factoren betrok-
ken bij Ca homeostase en botcel activiteit, niet causaal beboeven te zijn. De 
regula tie van het vitamine D metabolisme en bet werkingsmechanisme van het 
meest active vitamine D metaboliet 1,25-dihydroxyvitamine D (1,25-(0H),D) 
op zijn doelwitorganen worden eveneens in Hoofdstuk III besproken. In klini-
scbe zin zijn voor de regulatie van de vorming van 1,25-(0H)2 D in denier de 
concentratie van Ca, Pen bijschildklierbormoon in bet serum de belangrijkste 
factoren. De werking van I ,25-(0H),D is er vooral op gericht de influx van Ca 
(en P) in de extracellulaire r-uimte te stimuleren vanuit bet maagdarmkanaal, bet 
skelet en denier. 
Het werkingsmechanisme van I ,25-(0H),D he eft vele kenmerken van dat van 
een steroid bormoon: er zijn receptoren in bet cytoplasma en op de kern en er 
vindt de novo eiwitsynthese plaats via gen-activatie door het 1,25-(0H)2D. 
In Hoofdstuk IV wordt een literatuuroverzicht gegeven van bet effect van 
fysiologiscbe en suprafysiologische spiegels glucocorticoiden op regulatoren 
van de Ca bomeostase en de activiteit van botcellen. Een negatieve Ca en P 
balans als gevolg van een verminderde intestinale Ca en P absorptie en een 
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toegenomen renale klaring van beide mineralen lijkt van beslissende betekenis 
voor de pathogenese van glucocorticoid osteoporose. In bet licht hiervan is de 
regelmatig verhoogd gevonden bijschildklierhormoon spiegel in bet serum van 
deze patienten te beschouwen als een uiting van secundaire hyperparathy-
reoidie. Daarbij kan de bijschildklierhormoon secretie ook direct door gluco-
corticoiden worden gestimuleerd. Bij histomorfometrisch onderzoek van bot-
biopten van hypercortisolistische patienten worden veelal kenmerken gevonden 
van een verhoogde botajbraak en een verminderde botaanmaak. Aangezien 
deze histologisch manifest verhoogde botafbraak lang niet altijd gepaard gaat 
met een verhoogde concentratie bijschildklierhormoon in bet serum, lijkt bet 
erop dat de "response" van het botweefsel op parathyreoidhormoon versterkt 
kan zijn onder invloed van glucocorticoiden. Glucocorticoiden interferen met 
de botaanmaak door direkte remming van de synthese van botmatrix door de 
osteoblasten en door remming van de produktie van lokale groeifactoren of van 
hormonen die op indirekte wijze betrokken zijn bij de botvorming. 
Teneinde de effecten van een overmaat glucocorticoiden op de doelwitor-
ganen van vitamine D (bot, darm, nier) te kunnen verklaren is de mogelijke 
invloed van glucocorticoiden op het metabolisme (de activatie) van vitamine D 
zelfvrij uitgebreid onderzocht. Eensluidende conclusies kunnen uit deze onder-
zoekingen echter niet worden getrokken. 
Wij onderzochten bet effect van kortdurend hypercortisolisme op de activatie 
van vitamine D bij de mens (Hoofdstuk V). Tijdens toediening van 30 mg 
prednison per dag vonden wij bij 6 gezonde proefpersonen en 8 patienten met 
primaire hyperparathyreoidie binnen 1-3 dagen een stijging van de I ,25-(0H)2D 
concentratie in bet serum. Deze stijging bleek afhankelijk te zijn van de aanwe-
zigheid van de bijschildklieren, aangezien bij 5 patienten met hypoparathy-
reoidie tijdens toediening van 30 mg prednison per dag gedurende 3-4 dagen 
door ons geen stijging van het I ,25-(0H)2D gehalte van het serum werd waarge-
nomen. Bij normale mensen bleek infusie van hydrocortison reeds in 8 uur een 
dergelijke verhoging van de I ,25-(0H)2D spiegel te veroorzaken. Een verhoging 
van de gevoeligheid van bet renale !a-hydroxylase voor parathyreoidhormoon 
zou dit reactiepatroon kunnen verklaren, o.m. omdat geen veranderingen 
werden waargenomen van de concentraties van Ca, Pen bijschildklierhormoon 
in bet serum. Bovendien werd bij een patiente met hypoparathyreoidie een veel 
sterkere stijging van bet serum I ,25-(0H)2D na injectie van parathyreoid extract 
gezien als dit tesamen met hydrocortison werd toegediend. Bij de normale 
proefpersonen was de stijging van de serum 1,25-(0H)2D concentratie tijdens 
prednison toediening van voorbijgaande aard met terugkeren van de spiegel tot 
bet uitgangsniveau na 9 dagen toediening van prednison. Op grand van deze 
gegevens lijkt bet uitgesloten dat bij de mens een afname van de intestinale Ca 
absorptie, zoals regelmatig waargenomen tijdens behandeling met vergelijkbare 
dosering glucocorticoiden gedurende 1-2 weken, zou kunnen berusten op een 
stoornis in bet metabolisme van vitamine D. Anderzijds zou ook een compensa-
toire toename van de 1,25-(0H)2D spiegel in het serum, als gevolg van de 
remming van de absorptie van Cain de darm door glucocorticoiden, niet goed 
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verantwoordelijk kunnen zijn voor de waargenomen snelle en voorbijgaande 
stijging van de 1,25-(0H)2D spiegel. 
De wijze waarop glucocorticoiden in overmaat de intestinale absorptie van 
Ca verlagen werd door ons, op subcellulair niveau, onderzocht door gebruik te 
maken van zgn. "brush border membrane vesicles" bereid uit epitheelcellen van 
de pro xi male helft van de dunne darm van de rat (Hoofdstuk VI). Vijf dagen na 
injectie van een triamcinolon-depot-preparaat vonden wij een verminderde 
initiele snelheid van opname van Cain de vesicles, vermoedelijk als gevolg van 
een afname van het aantal of de activiteit van de Ca carriers in de membraan. 
Deze afname, die waarschijnlijk gepaard gaat met een vermindering van het 
transcellulaire Ca transport, bleek te kunnen worden tegengegaan door gelijk-
tijdige toediening van 1,25-(0H)2D3• In onze handen kon op het niveau van de 
"brush border" door een overmaat glucocorticoiden een afname van de Ca 
opname worden geinduceerd, die gelijk gericht is aan hetgeen door anderen 
gevonden is in experimenten met dunne darmlissen in vitro. Wij constateerden 
echter, bij onderzoek met in situ geisoleerde dunne darmlissen van de rat, dat 
onder deze oms tandigheden een verlaagde netto Ca absorptie door andere 
mechanismen word! bepaald. In het proximale dee! van de dunne darm bleek bij 
de met triamcinolon behandelde ratten de unidirectionele Ca-efflux (van lumen 
naar weefsel) gestimuleerd te zijn, positief gecorreleerd met de netto absorptie 
van water. Daarbij was een nog sterkere toename van de Ca-influx (secretie) 
o.i.v. triamcinolon verantwoordelijk voor de lagere netto absorptie van Ca 
(Hoofdstuk VII). 
Bij 6 van 10 patienten, die langdurig middelmatig hoge dosis glucocorticoiden 
gebruikten, bleek de fractionele intestinale absorptie van 4°Ca uit de voeding 
subnormaal (Hoofdstuk IX). Bij slechts I van deze 6 patienten was de in 5 uur 
geabsorbeerde fractie van oraal (met 200 mg 4°Ca als carrier) toegediend 47Ca 
ook verlaa.gd. Wanneer deze laatste meting representatief mag worden geacht 
voor de unidirektionele intestinale Ca-efflux, kan aileen een toegenomen endo-
gene secretie van Ca verantwoordelijk zijn voor deze discrepantie. Dit is in 
overeenstemming is met de uitkomsten van onze darmlis experimenten bij de rat 
(Hoofdstuk VII). Onder behandeling met 10'-(0H)D3 (2 p.g dd.) gedurende 6 
maanden kwam de geabsorbeerde fractie van Ca uit de voeding weer op nor-
maal niveau bij de patienten die met glucocorticoiden werden behandeld, onder 
toename van de fractionele 47Ca absorptie tot supranormaal. 
Het effect van behandeling met !0'-(0H)D3 (2 p.g dd.) op de botafwijkingen 
bij langdurig gebruik van glucocorticoiden, werd nagegaan in een dub bel blind 
zg. "placebo-controlled" onderzoek van 6-9 maanden bij 14 patienten onder-
ling paargewijs overeenkomend in geslacht, leeftijd, onderliggende ziekte en 
dosis glucocorticoiden (Hoofdstuk VIII). Voor de biochemische parameters 
van de Ca huishouding: serum Ca, P, alkalische fosfatase, vitamine D metabo-
lieten en uitscheiding van Ca en hydroxyproline in de urine, werden aan het 
begin van het onderzoek over het algemeen normale waarden gevonden. Een 
uitzondering werd gevormd door de lage concentraties 24,25-(0H)2D in het 
serum, die bij meer dan de helft van de onderzochte patienten werden gevonden. 
Hoewel de concentratie bijschildklierhormoon in het serum bij slechts 1 van de 
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14 patienten verhoogd was, werd bij histomorfometrisch onderzoek van trabe-
culair bot uit de crista iliaca als regel een verhoogd aantal osteoclasten gevon-
den, veelal in combinatie met een te laag trabeculair botvolume. Onder behan-
deling met la-(OH)D3 stegen de fractionele intestinale 47Ca absorptie en de 
calciurie significant in vergelijking tot bij de met placebo behandelde patient( e), 
"gematched" als bovengenoemd. Na 6 maanden behandeling bleken de bij-
schildklierhormoon concentratie in het serum en de uitscheiding van hydroxy-
proline in de urine te zijn verlaagd, terwijl de concentraties van 1 ,25-(0H)2D en 
24,25-(0H),D in het serum stegen tijdens behandeling met la-(OH)D3• Histo-
morfometrisch onderzoek van trabeculair bot van een tweede biopsie, genomen 
na 6 maanden behandeling met lor-(OH)D3 dan wei placebo, toonde een afname 
van de botresorptie parameters bij aile met la-(OH)D3 behandelde patienten. 
Het verloop van het trabeculaire botvolume was steeds meer positiefbij de met 
la-(OH)D3 behandelde patient in vergelijking tot de met placebo behandelde 
"partner". Er werden geen verschillen in verloop van de parameters voor bot-
vorming (osteoblastenzomen en osteoidzomen) gevonden bij de paarsgewijze 
vergelijking van de patienten. 
Naar aanleiding van de onderzoeksresultaten beschreven in dit proefschrift, 
wordt in Hoofdstuk X een concept gegeven van de pathogenese en van de 
mogelijkheden tot behandeling van de door glucocorticoiden teweeggebrach te 
botaandoening met actieve vitamine D derivaten of -metabolieten. Hierbij 
wordt gepostuleerd dat onder invloed van een overmaat glucocorticoiden de 
gevoeligheid van de niertubuli en de (pre)osteoclasten voor de werking van 
bijschildklierhormoon toeneemt. 
Een antagonisme tussen glucocorticoiden en vitamine D komt niet aileen tot 
uiting op het niveau van de Ca opname in "brush border membrane vesicles", 
maar ook in een verbeterde netto Ca absorptie in de darm en een anabool effect 
op de trabeculaire botmassa bij behandeling van patienten, die langdurig gluco-
corticoiden gebruiken, met een la-gehydroxyleerd derivaat van vitamine D. 
Het blijft onduidelijk ofhet positieve effect op de botmassa een gevolg is van de 
suppressie van de bijschildklierhormoon secretie of dat het actieve vitamine D 
metaboliet ook als "groeifactor" functioneert. 
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VERANTWOORDING 
Dit proefschrift kwam tot stand op de afdelingen lnwendige Geneeskunde Ill, 
Pathologische Anatomie I en Biochemie I. 
!-let was niet in ieder opzicht gemakkelijk als internist op de praktische inge-
stelde afdeling Heelkunde werkzaam te zijn en tegelijkertijd een onderzoek met 
preklinische aspect en te voltooien. Tach had ik dit niet will en en kunnen missen en 
ik dank met name Eveline Ong voor de gelegenheid die ik hiervoor heb kunnen 
nemen. 
Aile anderen die op enigerlei wijze behulpzaam waren bij het tot stand komen 
van dit proefschrift wil ik bedanken, oak degenen die ik hier niet zal noemen. 
Reeds in een vroeg stadium van mijn opleiding tot internist wist Prof. Bir-
kenhager mijn belangstelling te wekken voor botstofwisseling en wei speciaal voor 
een aspect dat hem zelf reeds langer bezighield: corticosteroidosteoporose. Zijn 
nooit aflatend enthousiasme, aansluitend bij mijn vasthoudendheid (c.q. 
"drammen"), was voor mij een belangrijke steun en stimulans. Dit resulteerde in 
een samenwerking waarvan ik heel veel heb geleerd. 
Dorie Birkenh.iiger "'voerde" mij, met grote kennis van zaken, in in de wereld 
van de bothistomorfometrie en zij mat met veel gevoel voor detail en geduld, 
geholpen door Ad Rietveld, de botbiopten van het patienten onderzoek. 
Vee! dank ben ik verschuldigd aan Hugo de Jonge voor het onderricht in de 
eigenschappen van zijn "borstelzoomblaasjes" en voor zijn inzet bij mijn bege-
leiding. Hierdoor kon mijn inzicht in de invloed van hormonen op calciumtran-
sport in de darm zich ontwikkelen. 
Cootje van Aller, Cok Buurman, Desiree Peul, Ed de Kam, Marcel van Edixho-
ven en Ronald Lammers hebben op voortreffelijke wijze de diverse laboratorium-
onderzoeken uitgevoerd. Theo Visser stood altijd klaar voor bet oplossen van 
problemei1 bij de wispelturige bepaling van vitamine D metabolieten. Ook de 
laboranten van bet Centraal Klinisch Chemisch Laboratorium (hoofd Dr. B. G. 
Blijenberg) past een woord van dank. Zij waren in staat en bereid ook in de "kleine 
uurtjes" serum calciumbepalingen te verrichten. 
lk dank Wil Hackeng en Roger Bouillon voor de bepalingen van bijschildklier-
hormoon en vitamine D bindend eiwit die in hun laboratoria werden verricht. 
De botdensitometrie en de absorptietesten met radioactief calcium werden 
nauwgezet uitgevoerd door Marcel van de Pluym op de afdeling Nucleaire 
Geneeskunde (Drs. W. Bakker). 
!-let personeel van de balansafdeling, Joke van Vure, Cootje van Aller, Marijke 
Hengeveld en Henny van der Stel-van de Berg, is op onnavolgbare wijze een steun 
geweest voor de patienten die aan bet onderzoek deelnamen, zowel in menselijk 
opzicht als bij bet praktisch uitvoeren van diverse proeven. 
!-let personeel van de interne afdelingen 4 Zuid en 4 Noord was behulpzaam bij 
het verzamelen van patientengegevens, waarvoor ik hen zeer erkentelijk ben. 
Secretariele hulp bij bet verwerken van de publica ties e~1 bet uittypen van de 
definitieve tekst van het proefschrift werd verleend door Dieneke van Wessem, 
Ankie Bos-Voogd en Yolande te Giffel. 
Paul Schmitz (afdeling Biostatistica) gaf advies bij het statistisch bewerken van 
de diverse resultaten. 
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De figuren en tekeningen in het proefschrift zijn uitgevoerd door de Audio-
visuele Dienst. Kees de Vries gaf de omslag zijn definitieve vorm. 
De firma Leo Pharmaceutische Producten Nederland leverde de la-hydroxy-
cholecalciferol en placebo tabletten voor de klinische trial. Met name Otto 
Bauermann heeft ervoor gezorgd dat het proefschrift in zijn huidige vorm kan 
verschijnen. 
Speciaal wil ik de patienten bedanken die bereid waren deel te nemen aan de 
diverse onderdelen van het onderzoek. Hun loyale medewerking was zeker niet 
aileen ingegeven door eigenbelang. 
Mijn gezin, Birgit, Annemarie en Saskia, is misschien wel het meest van allen 
betrokken geweest bij het tot stand komen van dit proefschrift, maar gelukkig 
werd deze "schepping" overvleugeld door de geboorte van onze jongste dochter, 
Hanneke. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 24 oktober 1949 te Dordrecht geboren. 
Na het behalen van het eindexamen Gymnasium ,8 aan bet Gemeentelijk Lyceum 
te Dordrecht in 1968, studeerde hij geneeskunde aan de Medische Faculteit te 
Rotterdam. Op 13 december 1974!egde hij het artsexamen af. Daarna volgde hij 
gedurende I jaar de beroepsopleiding tot huisarts en vervulde vervolgens zijn 
militaire dienstplicht bij de Koninklijke Landmacht. In 1976 ging hij in opleiding 
tot internist op de afdeling Inwendige Geneeskunde III tevens Klinische Endocri-
nologie van het Academisch Ziekenhuis Dijkzigt te Rotterdam (hoofd: Prof. Dr. 
J.C. Birkenhager). Op I aprill982 volgde inschrijving in bet specialistenregister. 
Thans is hij werkzaam als internist op de afdeling Algemene Heelkunde van het 
Dijkzigt Ziekenh uis. 
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